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ABSTRACT OF THE DISSERTATION 
 
Coordinate interstitial deletions of Retinoblastoma (RB1) and Neurobeachin 
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Numeric or structural chromosomal abnormalities are detected in nearly all 
patients with plasma cell dyscrasias, including primary amyloidosis, monoclonal 
gammopathy of undetermined significance (MGUS) and multiple myeloma (MM).  
Chromosome 13 deletions, most frequently monosomy 13, are detected in 10-
20% of MM cases by routine cytogenetics or metaphase fluorescent in situ 
hybridization (FISH) and are a significant predictor of shortened survival. 
Previous efforts to map somatically acquired DNA copy number losses on 
chromosome 13 have been limited by their low resolution. To identify DNA copy 
number losses on chromosome 13 at high resolution, we used genomic DNA 
isolated from CD138 enriched bone marrow cells (tumor) from twenty patients 
 xiv 
with MM, monoclonal gammopathy of undetermined significance (MGUS) or 
amyloidosis. We used matched skin biopsy (normal) genomic DNA to control for 
copy number polymorphisms and a novel aCGH array dedicated to chromosome 
13 to map somatic DNA gains and losses at unprecedented resolution (>385,000 
probes; median probe spacing 60bp). We identified RB1 and NBEA as being 
coordinately affected by copy number loss in MGUS and MM. To characterize 
these genes in the context of myeloma biology, we performed sequence and 
expression analysis on RB1 and found exonic mutations affecting RB1 were 
extremely rare, RB1 levels were decreased in patient samples harboring 
monosomy 13, and RB1 protein phosphorylation was not common. Expression 
analysis of NBEA revealed most patient samples harboring monosomy 13 had 
reduced NBEA, but to our surprise, a subset harbored high levels. Analysis of 
Nbea in hematopoietic tissues revealed although it was detected in thymus and 
spleen, using a fetal liver transplantation assay, Nbea was dispensable for 
hematopoietic development. Future studies investigating cooperation of RB1 and 
NBEA in plasma cell dyscrasias are warranted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
 
Introduction 
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1.1 Plasma cells are terminally differentiated B cells responsible for 
antibody production  
Plasma cells are terminally differentiated B cells whose function is to produce 
and secrete antibodies in response to antigen exposure. Their development in 
adults begins in the bone marrow stemming from the common lymphoid 
precursor (CLP) that gives rise to mixed B, T and natural killer cell progeny.  
Primitive B cells undergo regulated changes as they differentiate into mature B 
cells ready to exit the bone marrow. These changes are marked by cell surface 
expression of specific proteins representing successful recombination events 
required for formation of the B cell receptor (BCR).  
 
Antibodies are comprised of two identical heavy chain subunits and two identical 
light chain subunits.  There are two different parts of an antibody that help it 
function effectively. First, the variable region, comprised of both heavy and light 
chains, is responsible for antigen recognition. Multiple mechanisms exist to 
increase the diversity of this region, ensuring maximal affinity for antigen targets. 
These include introduced mutations during VDJ end joining that occurs early in B 
cell development, and later, during somatic hypermutation that occurs in germinal 
centers (discussed below).  The second part of an antibody molecule is the 
constant region, comprised of heavy chains, of which there are five isotypes: 
µ,α,γ,ε,δ. These are each responsible for activation of different downstream 
pathways best suited to trigger effective immune responses.  
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Antibody production involves DNA rearrangements affecting both heavy and light 
chain molecules.  Their formation marks the different stages of early B cell 
development in the bone marrow that all occur before these cells have ‘seen’ 
antigen. Pre/pro-B cells, distinguished from CLPs by expression of B220, have 
not yet begun DNA rearrangements required for antibody formation. Heavy 
chains are formed first by recombination of diversity (D) to junction (J) segments, 
and then the variable (V) segments are recombined to DJ segments. Pro B cells 
have begun to rearrange their heavy chain loci and upon completion of 
successful formation of VDJ segments, are now termed early Pre-B cells. Late 
Pre-B cells are defined by detection of light chain rearrangement. Finally, upon 
completion of a functional cell surface expressed antibody (the BCR), these cells 
are now mature B cells ready to exit the bone marrow and home to the 
secondary lymphoid organs, lymph node and spleen.   
 
There are multiple types of B cells in the spleen including follicular (B2), marginal 
zone (MZ), and B1, each with different cell surface markers but all with the ability 
to mature into plasma cells. B2 cells predominate in number compared to the 
minor types MZ and B1 B cells. The latter two types contribute the first line of 
antibody-mediated defense, which is rapid, short-lived, and results in production 
and secretion of low-affinity antibodies. Long-lived plasma cells are mainly 
derived from the B2 cells [1] that respond to antigens presented by splenic 
dendritic cells and require CD4 T cells.  
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B2 cells migrate into Germinal Centers, a zone in the spleen comprised of rapid 
proliferation, where they mature into centroblasts. They will undergo two DNA 
modifying events including Somatic hypermutation (SHM) and class-switch 
recombination (CSR).  Both events involve activation-induced cytidine 
deaminase (AID), the enzyme responsible for deaminating a cytosine residue 
resulting in a uridine:guanosine (U:G) mismatch. In SHM, this mismatch can be 
repaired by a variety of mechanisms. First, the uridine can be interpreted as a 
deoxythymidine, leading to an adenine-thymidine base pair. Alternatively, uracil 
DNA glycosylase can recognize the uracil, remove it, and then it can be fixed by 
short patch base excision repair or mismatch repair. The involvement of low 
fidelity DNA polymerases enhances the chance for mistakes. These events occur 
within the variable region of antibody only, ultimately leading to generation of B 
cells with the ability to generate antibody with high affinity for antigen.  
 
CSR also involves AID, which generates double stranded breaks within the 
‘switch regions’ located between the sequences encoding for the different 
subtypes of heavy chain locus on human chromosome 14. This leads to 
intrachromosomal deletion recombination and production of transcripts encoding 
one type of heavy chain. Long lived, post germinal center plasma cells ultimately 
leave secondary lymphoid organs and home back to bone marrow. Mistakes 
occurring in the germinal center DNA modifying processes are believed to be  
responsible for chromosomal abnormalities found in PC diseases, since if breaks 
are not repaired properly, translocations and mutations occur.  
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1.2 Multiple Myeloma (MM) 
 
Multiple myeloma (MM) is a malignancy of terminally differentiated bone marrow 
plasma cells. It is the second most common hematological cancer in the United 
States, responsible for 2% of all cancer deaths. It accounts for approximately 
12,000 deaths a year and remains incurable in most patients.  MM (and MGUS- 
see below) prevalence is twice as high in African Americans than Caucasians [2]. 
Myeloma incidence progressively increases with age and rarely affects persons 
under the age of 30 (less than 0.3%) [3]. During the period 2000-2004, in the US 
the median age of diagnosis of MM was 71 years based on US Surveillance 
Epidemiology and End Results Programme (SEER). 
 
Myeloma is a progressive tumor with multiple defined stages. Smoldering 
(asymptomatic) multiple myeloma (SMM) is slow growing and may not progress 
for months or years. SMM is defined by greater than 10% PCs in the bone 
marrow and monoclonal protein greater than 3g/dl without end stage damage 
such as osteolytic bone lesions (Table 1). Also asymptomatic, indolent myeloma 
is similar to SMM, but patients may have mild anemia or a few bone lesions.  
 
Increased numbers of PCs in the bone marrow, renal failure, osteolytic lesions 
and anemia characterize advanced (symptomatic) myeloma (Table 1). These 
patients are treated immediately with high dose chemotherapy, stem cell 
transplants and/or other drugs including Thalidomide, Bortezomib, Pamidronate 
or Zoledronic acid (www.mmrc.com). Myeloma remains an incurable disease, 
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although patients are living longer due to newer therapies. Identification of MM 
cells outside the bone marrow cavity (extramedullary) defines aggressive MM 
(called primary or secondary plasmacytoma depending if prior MM was 
diagnosed).  During this advanced disease, myeloma cells have high rates of 
proliferation, and it is only during this advanced disease where cell lines have 
been isolated.  
 
1.3 Monoclonal Gammopathy of Undetermined Significance (MGUS) 
Like MM, MGUS is a disease associated with age. It is found in 2% of persons in 
the general population 50 years of age or older, and ~3% of patients age 70 and 
older [4]. MGUS is clinically defined by plasma cell percentages within normal 
range (<10%), but detection of monoclonal antibody in the serum or urine (levels 
less than 3g/dl; Table 1). The risk of developing MM from prior MGUS is ~1%, 
per year of having MGUS, and most patients die of other causes before ever 
developing overt MM [4]. Although the total numbers of plasma cells are in the 
normal range, it is reported that in order to actually detect monoclonal antibody, 
at least 5X109 clonal cells are required, representing at least 30 cell doublings 
[5]. MGUS cells therefore at some point undergo cell division, in addition to not 
being eliminated via apoptosis.  
 
1.4 MGUS likely always precedes MM 
MGUS can be (but is not always) detected prior to development of overt 
myeloma, and, although controversial, is posited to be a “premalignant” tumor. It 
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is a current interest in the field to determine whether all MM has a prior MGUS 
phase, since if so, myeloma prevention could ultimately become a reality. The 
difficulty in determining whether MGUS precedes all MM is the lack of patient 
data prior to MM diagnosis. Two recent studies provide evidence that MM is 
always preceded by an MGUS. First, a study presented at the American Society 
of Hematology Meeting (San Francisco, 2008) [6] analyzed retrospectively, 
serum samples from active duty service members and found most MM patients 
had a detected plasma cell serum abnormality up to 2.5 years prior to MM 
diagnosis.  Additionally, a very recent paper [7] examined patients for 1-8+ years 
via the prostate, lung, colorectal and ovarian screening trial, and found 
essentially all patients diagnosed with MM had a prior detection of monoclonal 
antibody. These data suggest MGUS is a preclinical stage and studies to 
elucidate ways to prevent MM are warranted.   
There is much interest in identifying risk factors associated with progression from 
MGUS to MM. It is known MGUS patients with higher amounts of monoclonal 
protein at diagnosis, or monoclonal antibody of IgA or IgM  (versus IgG) subtype 
have an increased risk of progression to MM [4]. Abnormal serum kappa/lambda 
ratio also confers higher risk for MGUS patients [8].  
 
1.5 Primary Amyloidosis 
Primary Amyloidosis is a PC disorder characterized by overproduction of 
immunoglobulin light chains that form insoluble fibril deposits in a variety of 
organs including heart, kidney, liver, nerves, and/or bowel. This leads to organ 
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dysfunction and if not treated, median survival of 10-14 months.  Amyloidosis 
PCs have many of the same chromosomal abnormalities detected in MGUS and 
MM patient samples (discussed below) [9].  
 
1.6 Chromosomal abnormalities in plasma cell dyscrasias  
Numeric or structural chromosomal abnormalities are detected in nearly all 
MGUS and MM patients [10] and can be divided into groups (Figure 1) based on 
chromosome number.   About half of MM is hyperdiploid (48-75 chromosomes), 
characterized by trisomies usually involving chromosomes 3, 5, 7, 9, 11, 15, 19 
and 21.  Non-hyperdiploid myeloma is comprised of hypodiploid, (<45 
chromosomes), pseudodiploid (44-47 chromosomes), or near tetradiploid (75 or 
more). Near tetraploid appears to be 4N duplications of pseudodiploid or 
hypodiploid. Therefore, these three groups are usually grouped together as non-
hyperdiploid (<45 chromosomes or >75 chromosomes) [11]. This group is 
distinguished by lack of trisomies, and presence of primary translocations that 
juxtapose the strong heavy chain enhancers (IgH) located on chromosome 14 
with variant partner chromosomes. These translocations are found in a higher 
percentage of non-hyperdiploid cells (>70%) vs. of hyperdiploid  (<40%) of 
hyperdiploid MM [12]. The breakpoints within the IgH locus occur mostly at 
switch regions, but can also occur within VDJ sequences. These are thought to 
be mediated either by errors in switch recombination or somatic hypermutation. 
Additionally, since these mistakes occur during normal processes during B cell 
maturation within a germinal center, they are believed to be tumor-initiating 
events. 
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Within primary IgH translocations, the IgH locus is translocated to a variety of 
partner chromosomes at different frequencies (Table 2). The two most common 
translocations are the t(11;14)(q13;q32) and the t(4;14)(q32q23). The t(11;14) 
correlates with good prognosis, [13, 14] while the t(4;14) predicts poor prognosis 
[15]. Secondary translocations are detected in patient samples with advanced 
disease. In contrast to primary translocations, secondary translocations involve 
the IgH locus less and are structurally complex [12]. One of the common targets 
of secondary translocations is the c-MYC oncogene.  In addition to secondary 
translocations, late-stage MM samples harbor mutations affecting Ras, FGFR3, 
and/or P53.  
 
1.7 Monoallelic deletion of chromosome 13 is associated with poor 
prognosis 
Monoallelic deletion of chromosome 13 is detected in 30-50% of MGUS and MM. 
It is associated with reduced patient survival and decreased time to relapse, [11, 
15-18] although this association has been complicated by its method of 
detection. Analysis of monosomy 13 in PC dyscrasias is performed by 
cytogenetics, metaphase-fluorescent in situ hybridization (M-FISH), interphase 
FISH  (I-FISH), or comparative genomic hybridization (GCH). Cytogenetics and 
M-FISH require cell proliferation in culture, which is not needed for the latter two 
analyses. Because of this, up to one third of cytogenetic analyses fail and are 
uninformative.  Consistent with this, higher percentages of chromosomal 
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abnormalities are found in I-FISH [11].  
 
Multiple reports (using either interphase or metaphase methods) report 
monosomy 13 is associated with poor survival [11, 15-18]. However, it has 
become clear that only metaphase (cytogenetics or M-FISH) detected del 13 
associates with poor survival [15,16]. This becomes apparent if samples with del 
13 by I-FISH and M-FISH (or cytogenetics) are separated from those detected by 
I-FISH only. If the deletion is detected only by I-FISH, the poor survival 
association goes away [15,16]. These analyses highlight that there is a currently 
unknown abnormality/factor that confers the ability of these cells to grow in 
culture, which is contributes to the poor prognosis of those patients. 
 
Monosomy 13 is found both hyperdiploid and non-hyperdiploid samples, but is 
found in a higher percentage of hypodiploid tumors [16]. Hypodiploid status is 
associated with reduced patient survival compared to non-hyperdiploid tumors 
[19]. Cytogenetically detected del 13 confers poor outcome to both hyperdiploid 
and non- hyperdiploid patients, [20] but the reverse analysis revealed that 
dividing del 13 patients by ploidy status does not worsen patient outcome [15, 
20]. This suggests poor prognosis is determined by monosomy 13.  
 
Monosomy 13 is highly associated with the t(4;14)(q32;q23) translocation, also a 
predictor of poor patient prognosis [15]. Since almost all t(4;14) positive samples 
harbor monosomy 13, it is difficult to distinguish which abnormality is the cause 
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of the poor patient outcome. Monosomy 13 samples that do not have t(4;14) still 
predict poor outcome.  
 
If monosomy chromosome 13 were directly involved in the progression from 
MGUS to MM, then one would predict detection of monosomy 13 would be 
present in a lower percentage of MGUS samples vs. myeloma samples, 
representing MGUS patients progressing faster to MM.  Although reported in 
limited studies [21], more reports have found this not to be true [17,22]. Instead, 
the detection of monosomy 13 in MGUS at similar levels to MM supports the 
conclusion that monosomy 13 is an initiating event in PC transformation.  
 
1.8 Chromosome 13 Mapping Studies  
Previous efforts have been made to identify the important tumor- promoting 
regions on chromosome 13. Mapping studies using comparative genomic 
hybridization (CGH) analysis with 10Mb resolution identified 13q14-q21 and 
13q32-34 as regions on chromosome 13 commonly lost [23-25]. Fluorescent In 
Situ Hybridization (FISH), which probes for the presence or absence of known 
sequences, but with better resolution (1Mb) has highlighted similar regions [26-
29]. Whole genome array CGH (0.73Mb resolution) combined with gene 
expression analysis identified CUL4A (13q34) as a potentially relevant gene 
located within a 0.77Mb deletion on chromosome 13 [30]. Single nucleotide 
polymorphism (SNP) analysis (10Kb resolution) revealed a 1.9Mb minimally 
deleted region (MDR) in one patient spanning 13q13.3 to q21.3 [31].  
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The relatively low resolution of these studies has precluded identification of 
specific genes targeted by chromosome 13 deletions. The focus of this thesis 
was to indentify genes on chromosome 13 affected by copy number loss in 
MGUS, amyloidosis and myeloma patient samples. To this end, we employed 
high resolution aCGH using a novel, custom designed chromosome 13 focused 
array (Nimblegen) with median probe spacing of 60bp, on DNA isolated from 
primary CD138 selected cells with patient matched normal controls. We found 
the retinoblastoma (RB1) and neurobeachin (NBEA) genes were coordinately 
affected by copy number decrease in multiple patient samples. The focus of the 
thesis based on this result has been to characterize these two genes in PC 
diseases.  
 
 
1.9 Retinoblastoma (RB1) tumor suppressor 
Our aCGH analysis (Chapter 2, below) identified RB1 as being coordinately 
deleted with Neurobeachin (NBEA) in multiple patient samples taken from 
patients with MGUS or MM. RB1 was the first identified tumor suppressor gene, 
and is highly studied, as disabling the “RB1 pathway” is believed to be essential 
for virtually all tumor formation [32]. Mutations in, or deletions of, both copies are 
causative for development of retinoblastoma tumors in humans. Observations of 
retinoblastomas led to Knudson’s famous “two hit” model of tumor suppressor 
genes. Knudson observed patients with inherited predisposition to retinoblastoma 
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and correctly predicted that one defective tumor allele was inherited, and the 
other was somatically mutated [33].  
 
RB1 is a nuclear phosphoprotein that functions in multiple cellular processes 
including cell cycle, apoptosis, differentiation, and senescence. Its most well 
studied function is to inhibit cell cycle, which is regulated by phosphorylation. 
Hypo-phosphorylated is the “active” form of RB1 that represses transcription of 
cell cycle-promoting genes in two ways. First, RB1 can directly to bind to the 
transactivation domain of the E2F transcription factor [34, 35]. Second, while 
RB1/E2F complexes bind DNA, RB1 can recruit chromatin remodeling enzymes 
that downregulate gene expression [36-39]. Both events prevent transcription of 
E2F targets including genes required for replication, DNA metabolism and 
synthesis, cyclin E, and cyclin A [32, 40].  
 
RB1 has 16 serine/threonine phosphorylation sites whose phosphorylation status 
changes throughout cell cycle. RB1 gets partially phosphorylated during the cell 
cycle by cyclin dependent kinase (CDK, CDK4/CDK6) - Cyclin D (and then E) 
complexes.  CDKs require cyclins for active kinase activity. There are two protein 
families that act to inhibit cyclin/CDK complexes from phosphorylating RB1. First, 
the INK family (P16INK4a, P15INK4b, P18Ink4C, P19Ink4D) can specifically block the 
kinase activity of CDKs.  Second, the “Cip/Kip” family (p27KIP1, P21CIP1 and 
p57Kip2) can bind to and sequester cyclins from CDKs. Both of these negative 
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regulators, when intact, prevent phosphorylation (and therefore inactivation) of 
RB1. Together, these proteins comprise the “RB1 pathway”. 
 
1.10 Inactivation of RB1 pathway occurs via mutation, deletion, 
methylation, or phosphorylation  
Inactivation of the RB1 pathway occurs in different ways in a different tumor 
types.  Deletion or mutation of RB1 is found in retinoblastoma, breast, bone, 
brain, bladder, and some lung cancers. However, genetic inactivation of RB1 is 
not universal to all cancers, including those with heterozygous RB1 mutations 
[41]. In many tumors, the remaining RB1 is inactivated post-translationally by 
phosphorylation.  This occurs via deletion, mutation or methylation of the INK4a 
locus (CDKN2A) affecting p16. Alternatively, over-expression of Cyclin D, (which 
can activate CDK4/6) also results in hyper-phosphorylated RB1. Together, 
multiple mechanisms inactivate RB1. 
 
1.11 Neurobeachin (NBEA) is a BEACH domain containing protein 
implicated in vesicle trafficking 
Neurobeachin (NBEA, BCL8B) was identified in our study as being affected by 
copy number decrease by high-resolution aCGH analysis in plasma cell 
dyscrasias (Chapter 2, below). NBEA is a large gene whose genomic sequence 
spans 730Kb that produces a 9.5Kb transcript encoding a 327KDa protein. It is 
the largest member of the BCL8 gene family containing BCL8A-E [42]. All 
members of the family except NBEA are pseudogenes or produce sterile 
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transcripts [42]. It has homologs in mice (Nbea), C elegans (Sel-2), which is 
shared with LRBA [43] and drosophila  (rugose, DAKAP550). NBEA protein 
encodes multiple domains (Figure 1), including a Pleckstrin Homology (PH), 
BEACH, WD40 and a PKA binding.  
 
NBEA is one of a group of five known mammalian genes containing a highly 
conserved BEACH (beige and Chediak-Higashi) domain. BEACH domain 
containing proteins are found in Drosophila melanogaster (six), Caenorhabditis 
elegans (three), Arabidopsis thaliana (five), Dictyostelium discoideum (six) and 
Saccharomyces cerevisiae (one). 
 
Homozygous deletions within or upstream of the BEACH domain (leading to 
truncated proteins) in the Lysosomal Trafficking Regulator gene (LYST,CHS1) 
are found in patients with Chediak-Higashi Syndrome (CHS) [44-46]. This is a 
rare, autosomal recessive disorder characterized by variable albinism, bleeding 
tendency, progressive neurologic abnormalities and severe immunodeficiency 
with lack of natural killer cell activity. The cellular hallmark of CHS is enlarged 
lysosomal and lysosomal related organelles in almost all granulated cells, [47-49] 
(suggesting the BEACH domain regulates vesicle size, structure or function 
[47,49].  
 
Other mammalian BEACH encoding proteins are implicated aspects of vesicle 
function. LPS-Responsive Vesicle Trafficking, Beach and Anchor containing 
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(LRBA, BGL, CDC4L), which like NBEA, encodes a Protein kinase A (PKA) 
binding domain (discussed below) is implicated in vesicle release in polarized 
cells [50]. Neutral Spingomyelinase Activation Associated Factor (NSMAF, FAN) 
encoding the protein FAN is implicated in TNF signaling and activation of neutral 
sphingomyelinase. Nsmaf deficient mice have slightly enlarged lysosomes [51]. 
The protein encoded by the WD Repeat and FVYE Domain-containing 3 
(WDFY3, ALFY) gene binds Phosphoinositol 3 phosphate that regulates 
endocytic and autophagic trafficking [52]. Finally, NBEA is implicated in induced 
vesicular release at the neuromuscular junction [53, 54].  
 
Crystal structure analysis of the BEACH domain and the 130amino acids N-
terminal to it revealed it lies C-terminal to a Pleckstrin Homology domain that is 
not conserved by sequence, but by structure [55]. The BEACH domain physically 
interacts with the PH domain, suggesting these two domains function as a single 
unit [55].  Although PH domains can bind either to fatty acids or proteins, the 
interaction of the PH domain with the BEACH domain physically blocks the alpha 
helix known to mediate fatty acid binding, suggesting the PH domain of NBEA 
mediates protein-protein interactions [55].  
 
1.12 NBEA is a Protein Kinase A (PKA) Anchoring Protein (AKAP) 
In addition to the domains discussed above, NBEA encodes a PKA binding site. 
PKA the term used to describe its enzyme complex composed of four regulatory 
subunits (RIα,  RIβ ,RIIα and RIIβ) and two catalytic subunits (Cα and Cβ) with 
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serine/threonine kinase activity that is activated in response to increases in 
cAMP.  Murine Nbea binds to PKA regulatory subunits RIIα (Kd 10nM) and RIIβ  
(Kd: 30nM) [53]. Mouse and human NBEA are highly conserved within the PKA 
binding region, and therefore human NBEA is predicted to bind PKA, although 
this has not yet been shown. Neurobeachin is therefore characterized as an 
AKAP thought to localize PKA to correct cellular locations.  When levels of cAMP 
increase, PKA signaling only occurs at correct locations, which facilitates 
appropriate phosphorylation of downstream targets.  
 
1.13 NBEA expression is highest in brain 
NBEA transcripts and protein are detected at very high levels in both mouse and 
human brain [42, 53, 54, our own data]. Lower, but relatively robust transcripts 
are found in uterus, adrenal gland, ovary, testes, lung and kidney with even lower 
expression in heart, spleen, stomach, and small intestine  [42, 54]. Mice that lack 
Nbea die immediately after birth due to a block in synaptic transmission at the 
neuromuscular junction, supporting a functional role in the nervous system [54].  
 
1.14 NBEA spans the common fragile site, FRA13A 
Fragile sites are nonrandom, weak regions of the genome that have mostly been 
identified in vitro by culturing cells in the presence of agents that delay or inhibit 
replication, such as aphidicolin and then examining metaphase spreads. They 
have received considerable attention since breaks that result from fragile sites 
can result in translocations, deletion or gene amplification that may contribute to 
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cancer development. Common fragile sites are present in virtually all individuals 
while rare fragile sites are found in less than 5% of the population. There are 
over 80 common and at least 27 rare common fragile sites in the human genome 
[56]. Rare fragile sites occur due to mutation of di- or tri-nucleotide repeats and  
are detected at very low frequency [57], while the specifics of common fragile 
sites are not completely understood. 
  
NBEA spans the 650Kb common fragile site FRA13A [58]. FISH mapping 
revealed breaks within 650Kb of NBEA and were detected from intron one to 41, 
although most breaks (74%) were located in a 245Kb region spanning NBEA 
exons 34 to 40 [59]. Consistent with other common fragile sites, sequence 
analysis of the 345Kb region revealed that it is AT rich (65%) and lack the di or 
tri-nucleotide repeats found in rare fragile sites [58].  
 
The main goal of this thesis project was to identify genes with copy number loss 
in DNA isolated from purified tumor cells from patient samples with PC 
dyscrasias. We identified RB1 and NBEA as being coordinately affected by copy 
number loss (Chapter 2). Since we were interested in further characterizing 
these genes in the context of myeloma biology, we performed sequence and 
expression analysis on RB1 (Chapter 3), and expression and hematopoietic 
analysis on NBEA (Chapter 4).  The work presented in this dissertation, as with 
most scientific endeavors, leaves many questions and avenues to pursue. These 
are discussed in Chapter 5.  
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1.17 Figure 
 
 
Figure 1 
 
 
 
 
 
Figure 1. NBEA protein and exon structure 
A. NBEA protein domains. Numbers correspond to amino acids. B. 
NBEA exon structure. Some exons are numbered (top) and sizes of 
the four largest introns are shown on bottom.  
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Identification of chromosome 13 genes 
affected by DNA copy number decrease in 
MGUS and MM 
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O’Neal, et al.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions 
at 13q13 in patients with MGUS and multiple myeloma. Exp. Hem. 2009; 37:234-
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2.1 Abstract 
 
Chromosome 13 deletions, detected by metaphase cytogenetics, predict poor 
outcome in multiple myeloma (MM), but the gene(s) responsible have not been 
conclusively identified. We sought to identify tumor suppressor genes on 
chromosome 13 using a novel array comparative genomic hybridization (aCGH) 
strategy. We identified DNA copy number losses on chromosome 13 using 
genomic DNA isolated from CD138 enriched bone marrow cells (tumor) from 
twenty patients with MM, monoclonal gammopathy of undetermined significance 
(MGUS) or amyloidosis. We used matched skin biopsy (normal control) genomic 
DNA to internally control for copy number polymorphisms and a novel aCGH 
array dedicated to chromosome 13 to map somatic DNA gains and losses at 
unprecedented resolution (>385,000 probes; median probe spacing 60bp). Two 
distinct minimally deleted regions at 13q14.2 and 13q13 were defined that 
affected the RB1 and NBEA genes, respectively. RB1 is a canonical tumor 
suppressor previously implicated in MM. NBEA is implicated in membrane 
trafficking in neurons, PKA binding, and has no known role in cancer. Non-coding 
micro RNAs on chromosome 13 were not affected by interstitial deletions. Both 
the RB1 and NBEA genes were deleted in 40% of cases (8/20; 5 patients with 
monosomy 13 detected by traditional methods and three patients with interstitial 
deletions detected by aCGH). Our data suggest further investigation of RB1 and 
NBEA in MM is warranted.  
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2.2 Introduction 
 
Chromosomal abnormalities in plasma cell (PC) dyscrasias  
Multiple myeloma (MM) is a malignancy of terminally differentiated bone marrow 
plasma cells. It is the second most common hematological cancer in the United 
States, responsible for 2% of all cancer deaths. Overt MM can be preceded by 
Monoclonal Gammopathy of Undetermined Significance (MGUS), a premalignant 
tumor characterized by an accumulation of clonal plasma cells in the bone 
marrow. Primary Amyloidosis is a PC disorder characterized by overproduction of 
immunoglobulin light chains that form insoluble fibril deposits in a variety of 
organs. Amyloidosis PCs have many of the same chromosomal abnormalities 
detected in MGUS and MM patient samples [1.] 
 
Numeric or structural chromosomal abnormalities are detected in nearly all 
MGUS and MM patients [2] and can be divided into two main groups 
(hyperdiploid and non-hyperdiploid) based on chromosome number.   About half 
of MM is hyperdiploid (48-75 chromosomes), characterized by trisomies usually 
involving chromosomes 3, 5, 7, 9, 11, 15, 19 and 21.  Non-hyperdiploid myeloma 
is comprised of hypodiploid, (<45 chromosomes), pseudodiploid (44-47 
chromosomes), or near tetradiploid (75 or more). Near tetraploid appears to be 
4N duplications of pseudodiploid or hypodiploid. Therefore, these latter three 
groups are usually grouped together as non-hyperdiploid (<45 chromosomes or 
>75 chromosomes) [3].  
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Non-hyperdiploid MM is distinguished by lack of trisomies, and presence of 
primary translocations that juxtapose the strong heavy chain enhancers (IgH) 
located on chromosome 14 with variant partner chromosomes. The three most 
common translocations detected are the t(11;14)(q13;q32), t(4;14)(p16.3;q32), 
and t(14;16)(q32;q23) affecting the Cyclin D1, FGFR3/MMSET and c-MAF 
genes, respectively. The t(11;14) correlates with good prognosis, [4,5] while the 
t(4;14) predicts poor prognosis [6]. In disease progression, other genetic events 
are detected including secondary IgH translocations, c-MYC translocations, and 
mutations affecting Ras, and/or P53. Monosomy 13 is found both hyperdiploid 
and non-hyperdiploid samples, but is found in a higher percentage of hypodiploid 
tumors [7]. It is detected in 30-50% of MGUS and MM its detection by 
cytogenetic or M-FISH is a potent predictor of reduced patient survival and 
decreased time to relapse [6-9]. 
 
13q14 and 13q34 are regions previously implicated as affected by copy 
number decrease in MM 
Previous efforts have been made to identify the important tumor- promoting 
regions on chromosome 13. Mapping studies using comparative genomic 
hybridization (CGH) analysis with 10Mb resolution identified 13q14-q21 and 
13q32-34 as regions on chromosome 13 commonly lost [10-12]. Fluorescent In 
Situ Hybridization (FISH), which probes for the presence or absence of known 
sequences, but with better resolution (1Mb) has highlighted similar regions [13-
17]. Whole genome array CGH (0.73Mb resolution) combined with gene 
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expression analysis identified CUL4A (13q34) as a potentially relevant gene 
located within a 0.77Mb deletion on chromosome 13 [18]. Single nucleotide 
polymorphism (SNP) analysis (10Kb resolution) revealed a 1.9Mb minimally 
deleted region (MDR) in one patient spanning 13q13.3 to q21.3 [19].  
 
We employed high-resolution array CGH to identify genes on chromosome 13 
with DNA copy number loss. Our novel, chromosome 13 array enabled 
identification of recurring interstitial deletions involving 13q14.2 and 13q13. The 
high resolution of the array enabled mapping the MDR in 13q14 to exon 20 of 
RB1 encoding part of the ‘pocket domain’ responsible for binding E2F 
transcription factors [20,21]. All patients with an interstitial deletion affecting RB1 
also harbored a deletion within a novel MM gene, NBEA (13q13). Our data 
suggest that copy number loss of multiple genes on chromosome 13 including 
RB1 and NBEA could contribute to MM/MGUS biology.  
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2.3 Methods 
 
2.3A Patients 
  
Human bone marrow samples and skin punch biopsies were obtained during 
office visits after informed, written consent. Patient identification remained 
anonymous via use of Unique Patient Numbers (UPN). Cytogenetics and M-FISH 
were performed in clinic and those data were provided to us. 
 
 
2.3B Isolation of plasma cells (PC) 
 
Whole bone marrow was subjected to a ficoll gradient (Stem Cell Technologies, 
Vancouver, BC). Remaining mononuclear cells were stained with human CD138 
microbeads and run over an AutoMACS magnetic column on an AutoMACS Cell 
Separator (Miltenyi Biotec, Aubern, CA). Fluorescence activated cell-sorting 
analysis using a PE-CD138 human antibody (Miltenyi Biotec, Aubern, CA) 
confirmed  >97% purity (Figure 1). CD138+ and skin DNA was isolated using the 
Qiagen Miniprep Kit (Valencia, CA). 
 
2.3C Array CGH Platform  
The first 20 patient samples with ≥500,000 CD138+ cells were selected for 
aCGH, which required 1.5mg DNA. CD138+ (tumor) DNA was labeled with Cy3 
and skin (normal control) DNA was labeled with Cy5. The custom array 
contained 385,272 oligonucleotide probes. Nimblegen built, and performed probe 
design and sample hybridization to the custom array (www.Nimblegen.com). 
Sequence source for the probe design was HG17/UCSC (http://genome.ucsc.edu/).  
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2.3D Circular Binary Segment (CBS) Analysis 
Systematic CBS analysis [22] was performed using Signal Map Software 
(Nimblegen, Madison, WI).  Data was analyzed using a non-overlapping window, 
which averaged the signal intensity from each probe over a 600bp region. Since 
probes were spaced approximately every 60bp apart, each window averaged 10 
probes. This approach was used to condense the data and provided clean 
segment breaks. Systematic thresholds were set to eliminate false positives. 
Criteria for calling segments were: ≥3 data points involved (representing ~30 
probes; 1800bp) and log2 ratio <-0.25. Magnified plots were generated with 
Graphpad/Prism 4, Version 4.02 (Graphpad Software Inc, San Diego, CA). 
 
2.3E Process Control and whole chromosome plots 
Process Control analysis was performed on unaveraged data set (no windows 
were used to condense data). Data was normalized using qspline [23]. To 
eliminate outliers, the raw data for the skin (reference, control) samples from 
each patient was analyzed.  Probes with signal intensity >3X SD above the mean 
were discarded (range: 8,000-17,000, averaged 10,000 per patient  (2-4.4% of 
total). Process control employs techniques using a Shewhart control chart, [24] a 
graphical and analytical tool used in industry for quality control purposes. It is 
applied to aCGH analysis to determine which probe intensities are different 
enough from mean variability to be considered meaningful. Probe intensity ratios 
were considered “significant” if they satisfied: eight probes in a row on one side 
of the overall mean. They also had to pass either A) two of three probes in a row 
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beyond two units of overall SD, or B) four of five points in a row beyond one unit 
SD [25,26]. If an eight-probe region (representing   ~480bp) passed the criteria, 
the first and last of the eight probes were mapped (~3.8Kb).  Genes were 
mapped by aligning probes of interest to the Human Build 36.2 genome. Whole 
chromosome plots using this same data set were generated using the program 
[R] (Figure 2A).  
 
2.3F PCR and sequence analysis of microdeletion 
PCR was performed on original un-amplified patient genomic DNA. Control DNA 
was kindly provided by Rhonda Ries, Dept. of Medicine, Washington University 
School of Medicine, Lab of Timothy Ley (WUSM)). Primers: 
RBValFWD3:CCATTGCCCACAGTCAGAAA 
RBValREV3:GGTAGGGGAATAGGGGGTGA. Products were cloned into 
TOPO2.1 vector (Invitrogen, Carlsbad, CA) and sequenced at the Protein and 
Nucleic Acid Core Laboratories, Washington University. 
 
2.3G Real Time PCR 
Real time PCR assays were performed on the original, unamplified genomic DNA 
isolated from CD138 cells from patient samples using the Taqman Universal 
PCR Master Mix.  Primer concentration: 900nM; probe concentration: 2.5mM, 
10ng template. Reactions were run on 7300 Real Time PCR System, and 
analyzed using 7300 System Software (Applied Biosystems, Foster City, CA). 
RBRTFwd1:5’GAATTAGAACATATCATCTGGACCCTTT3’   
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RBRTRev1:5’GGTCCAAATGCCTGTCTCTCA3’RBExon20Probe:5’56FAMCCA
GCACACCCTGCAGAATGAGTATGAA36-TAMSp3’ 
Glypican6Fwd:5’TTCTGGTTCGGGCAAACTTG3’  
Glypican6Rev:5’GAAGGCGCCACTCAGACTGT3' 
Glypican6Probe:5’56FAMCGACCGCAGTTTGCCCAGCG36-TAMSp3’  
NBEARTF1:5’AATGGGTTACTACTGAAAACCTAGTGTAAA3’ 
NBEARTR1:5’TCGCCATCTAGTTTCATCAGTATACAG3’ 
NBEAProbe:5’56FAMCACAGAAAACTGAAATTGGGAGGCTTATGTGTAA36-
TAMSp3’. The DDCt method was used since control reactions confirmed equal 
efficiency of primer/probes. Reactions were performed in triplicate and repeated 
three (RB1) or two times (NBEA).  
 
2.3H I-FISH 
I-FISH was performed using standard techniques. Probes: LSI 13/RB1, and 
CEP7 (Vysis Inc., Downers Grove, IL, USA). For each hybridization, a minimum 
of 100 non-overlapping nuclei was analyzed.  
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2.4 Results 
 
2.4A Patient characteristics 
Deletions affecting chromosome 13 occur at similar frequencies in a variety of 
plasma cell dyscrasias, [3,11,16,27] so patients with the diagnosis of MM, 
MGUS, or amyloidosis, regardless of chromosome 13 status, were selected for 
array comparative genomic hybridization (aCGH). Twenty patients were selected 
solely on the basis bone marrow plasma cell yield after CD138 enrichment 
(Table 1, Table 2, Figure 1). We excluded low-yield samples to avoid the need 
for whole genome amplification (WGA), which can introduce bias or mutation 
(personal communication Matthew Walter, 2008). Genomic DNA was isolated 
from CD138-enriched bone marrow samples (tumor) as well as from patient-
matched skin biopsy samples (normal) controls. Patient-matched skin biopsy 
samples were an important internal control for copy number polymorphisms 
known to occur in healthy populations [28,29]. 
To identify DNA copy number alterations across chromosome 13 with the 
greatest possible resolution, we performed comparative genomic hybridization 
using a custom CGH array (Nimblegen Inc, Madison, WI) dedicated to 
chromosome 13. The custom array had 385,272 probes spanning the entire 
length of chromosome 13 with median probe spacing of 60 base pairs. 
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2.4B DNA copy number losses identified by circular binary segment 
analysis  
Array CGH data were plotted linearly along chromosome 13 using log2 tumor: 
germline signal intensity ratios. By eye, some regions of copy number change 
were obvious (Figure 2), but to systematically identify regions of DNA copy 
number loss across chromosome 13, we performed two independent, 
unsupervised analyses of the data. To identify minimally deleted regions (MDRs) 
across patient samples, we first used a CBS algorithm using stringent criteria to 
identify interstitial deletions [22]. 
By CBS analysis, eight of the 20 patient samples (40%) harbored at least one 
region of interstitial DNA copy number loss with a mean deletion size of 596Kb 
(range: 1.2Kb to 16Mb, Table 3). Among the eight patients with DNA copy 
number loss, the mean number of deletions was five (range: 1 to 13).  The 
finding of a greater number of chromosome 13 deletions than previously reported 
using lower resolution techniques [12-14] suggested that our strategy could be 
useful for finding novel regions on chromosome 13 contributing to plasma cell 
diseases. 
 
2.4C Array CGH identifies interstitial deletions not detected by FISH or 
cytogenetics 
We compared chromosome 13 status determined by aCGH to analyses of 
chromosome 13 using standard techniques including metaphase cytogenetics, 
 38 
metaphase fluorescent in situ hybridization (M-FISH) and interphase fluorescent 
in situ hybridization (I-FISH; Figure 2). Because the aCGH raw data were 
normalized to balance fluorochrome intensity, monosomy 13 (i.e. non-interstitial 
deletions) was undetectable via aCGH analysis. We therefore relied on clinical 
cytogenetic data for detection on monosomy 13 (Table 1, Figure 2). By 
cytogenetics, five of the 20 patient samples (25%) had monosomy 13 (Table 1, 
Figure 2). Additionally, two patients with monosomy 13 (22848 and 92896) also 
had aCGH-detected DNA copy number losses suggesting homozygous deletion 
at those loci (Table 3).  A 1200bp deletion in patient sample 22848 did not map 
to known genes or microRNAs at 13q31, while patient sample 92896 harbored 
two deletions affecting KATNAL1 and DNAJC3 genes.  
 
Notably, cytogenetic and FISH analysis failed to detect chromosome 13 DNA 
copy number loss in 25% of cases (5/20) that were positive by aCGH (Figure 2).  
This data demonstrates that high-resolution array CGH has the ability to detect 
chromosome 13 deletions undetected by standard FISH and cytogenetics. This 
result also highlights the utility of unbiased analysis of the entire chromosome to 
identify novel regions on chromosome 13 whose copy number changes could 
direct the study of genes relevant to MGUS and MM pathogenesis.   
 
2.4D Mapping of chromosome 13 genes affected by DNA copy losses 
To identify chromosome 13 genes whose loss could contribute to MM 
pathogenesis, we mapped all known genes that fell within the regions of copy 
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number loss identified by CBS analysis. We found 28 of 43 (65%) deleted 
segments mapped to at least one gene, rather than non-coding DNA (Table 3). 
None of the regions identified in our study mapped either of two micro RNA 
clusters on chromosome 13 known to undergo deletions or be downregulated in 
CLL [30]. (miR 15-16 at 13q14 and MiR 17-92 at 13q31.3) were not affected in 
our samples.  
 
To independently identify genes with copy number loss on chromosome 13, we 
performed a separate, unsupervised analysis of the data by using an 
independent Process Control algorithm [24] shown to reliably call aCGH probe 
signals that deviate significantly from baseline (Figure 3). This second analysis 
identified 216 probes that mapped to 42 genes (Table 4). Twenty of the 42 genes 
(48%) identified by Process Control were also identified by the CBS analysis, 
underscoring the robustness of the aCGH data set (Table 3).  
 
2.4E RB1 and NBEA are recurrent targets of interstitial deletions in MGUS 
and MM  
The region most affected in our patient group encompassed 13q12 to 13q14.3, 
(25 to 50Mb), Figure 2). CBS analysis of the log2 plots from three of five patient 
samples with interstitial deletions (58762, 64511, and 95295) revealed two 
distinct MDRs within 13q12-14.3 (Figure 2 shaded bars, Figure 4-5). Patient 
sample 95295 harbored two DNA copy number losses that were extremely small 
(106Kb and 1200bp, respectively) and defined the MDRs at 13q14.2 and 13q13 
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(Figure 2, 4-5, Table 3). Within 13q14.2, only the RB1 gene was affected in all 
three patient samples (Figure 4). Strikingly, the 13q14.2 MDR mapped to exon 
20 of RB1, encoding the ‘pocket domain’ of RB1 critical to its tumor suppressor 
function [30].  
Inspection of the log2 plots from the same three patient samples revealed each 
harbored a second and distinct interstitial deletion at 13q13, 13Mb centromeric to 
the RB1 locus (Figure 2, 5). This second 13q13 MDR mapped to a single gene 
not previously implicated in myeloma biology: neurobeachin (NBEA, BCL8B, 
Figure 5). Every patient sample in our set that harbored a deletion affecting RB1 
(three with interstitial deletions and five with monosomy 13) simultaneously 
harbored copy number losses affecting the novel myeloma associated gene 
NBEA (Table 3, Figure 2, 4-5). 
 
2.4F Confirmation of small interstitial deletion in patient sample 95295 
leads to identification of novel RB1 mutation 
Since the segment of DNA copy number decrease within RB1 in patient 95295 
was small (3.49Kb) and contributed significantly to the mapping of the 13q14 
MDR, we first performed PCR spanning the microdeletion on the same tumor 
and skin genomic DNA used in the aCGH analysis (Figure 4). Amplification of a 
truncated band and sequence analysis of the PCR product confirmed this 
deletion tumor-associated (Figure 4). This result confirms the novel micro-
deletion affecting RB1 in patient sample 95295. 
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To further characterize the small deletion in patient sample 95295, the PCR 
product was subcloned and sequenced. This revealed the deletion spanned 
3486bp total, removing 2813bp of intron 19, all of exon 20, and 527bp of intron 
20 (Figure 5). Additionally, in the middle of the deletion was an insertion of 435 
base pairs identical to another sequence on chromosome 13, 35Kb downstream 
of the RB1 locus and situated in the opposite orientation. This inserted sequence 
encoded a conserved splice acceptor and almost perfect branch sequence.  To 
determine whether splicing into this region, or around this region occurred, we 
amplified cDNA from this patient sample and performed sequence analysis. We 
found that the transcript had been spliced from exon19 directly to exon 21, 
skipping the potential splice acceptor site within the insertion. This transcript 
revealed deletion of exon 20 that predicts a truncated protein, which we refer to 
as RB1del20. 
 
Analysis of the RB1del20 sequence revealed that splicing from exon 19 to 21 
predicts a frame shift, such that there would be 17 unique amino acids followed 
by a stop codon. Therefore, this transcript is predicted to encode a truncated 
protein that would have 17 unique amino acids and a loss of 275 3’amino acids, 
with a predicted total size of about 70kD. Exon 20 encodes part of the ‘pocket 
domain’ comprised of the A and B regions, required for binding to E2F.  
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Some RB1 mutations are predicted to encode unstable transcripts resulting in no 
or very little protein expression [31]. We therefore sought to determine whether 
RB1del20 would result in either robust or no protein expression. Both WT full 
length RB1 and RB1del20 were subcloned into the MSCV expression construct, 
and these DNA’s were transfected into 293T cells. We found robust expression 
of both WT and RB1del20 protein (Figure 5). A point mutation within RB1, R661W 
is associated with low-penetrance retinoblastoma and lacks the ability to bind 
E2F [31].  Since our truncated RB1del20 lacks 113 AA of the B domain within the 
RB Pocket, it is highly unlikely it will retain the ability to actually bind E2F. 
Together, our aCGH analysis led to the identification of a novel RB1 mutation, 
predicting inactive RB1 protein in patient sample 95295. 
 
2.4G Confirmation of interstitial deletions affecting RB1 and NBEA genes 
To quantify and confirm the DNA copy loss across all three patient samples with 
interstitial RB1 deletions (58762, 64511 and 95295), real time PCR was 
performed on CD138 purified tumor genomic DNA (Figure 4). Consistent with 
the qualitative PCR, patient sample 95295 had virtually no signal using a primer-
probe set at this locus (fold copy number: 0.02). Patient samples 58762 and 
64511 had a fold copy number of 0.86 and 0.62, respectively, consistent with 
loss of one copy of RB1. These results are concordant with the aCGH log2 ratios 
for this region (average log2 ratio of probes that span microdeletion:  95295: -
0.977; 58762: -0.518; 64511: -0.754).  
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A similar analysis was used to quantify and confirm the interstitial NBEA 
deletions in patient samples 58762, 64511, and 95295. Consistent with the 
aCGH data, patient sample 95295 revealed homozygous deletion (fold copy 
number:  0.14). Patient samples 58762 and 64511 revealed heterozygous loss of 
NBEA (fold copy number: 1.22 and 0.9, respectively; Figure 6). These data 
confirm non-contiguous interstitial deletions on chromosome 13, affecting 
simultaneously the NBEA and RB1 genes in three of 20 patient samples (15%).  
 
2.4H Whole genome aCGH confirms large deletions detected within patient       
sample 95295 
We were fortunate to have enough DNA from patient samples 95295, which 
marked both MDR’s at 13q13 and 13q14.2. Whole genome aCGH (1.1Kb median 
probe spacing) analysis was performed on this sample (Figure 7) and revealed 
similar interstitial deletions to those found by the original analysis. The small 
deletion within RB1 was undetectable by this analysis, due to the lower 
resolution, and further highlighting the extremely high resolution of the 
chromosome 13 novel array. Together, a separate analysis confirms the changes 
we detected within patient sample 95295.  
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2.5 Discussion 
We used a novel ultra high-resolution aCGH strategy to map somatic 
chromosome 13 deletions with unprecedented resolution in 20 patients with MM, 
MGUS or amyloidosis. We used a custom CGH array dedicated solely to 
chromosome 13 (60bp median probe spacing) and genomic DNA from patient-
matched skin biopsy samples as controls to eliminate signal noise due to DNA 
copy number polymorphisms [28,29]. 
 
We avoided noise introduced by whole genome amplification strategies by using 
non-amplified genomic DNA from cases with high yields of CD138+ bone marrow 
mononuclear cells. Patients with low bone marrow tumor burden may therefore 
have been underrepresented in this study. However, analysis by standard 
techniques of FISH and cytogenetics detected chromosome 13 deletions at 
expected frequencies [3,6] (Table 1) suggesting our patients were generally 
representative of other MM, MGUS and amyloidosis cohorts. Although our 
detection of del[13] by I-FISH was lower than other reports, our analysis was 
performed on non-enriched paraffin embedded bone marrow samples, which 
likely explains this discrepancy.  
 
We found two regions of recurrent DNA copy number loss that were non-
overlapping and mapped to two genes: RB1, the canonical tumor suppressor at 
13q14.2, and NBEA at 13q13, a gene whose role in cancer is less clear.  Two 
independent, unsupervised analyses (CBS and Process Control) generated gene 
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lists affected in our patient set that largely overlapped  (Table 3-4) demonstrating 
the high quality of our aCGH data. Both lists included the RB1 and NBEA genes. 
Visual inspection of log2 plots at these loci in high-resolution and PCR confirmed 
the identification of these as bona fide deletion events (Figure 2, 3-7; data not 
shown). Extremely small (homozygous) deletions (3.49Kb and 106Kb) in a single 
patient (95295) significantly narrowed the MDRs we identified. In sample 95295, 
NBEA and RB1 were the only two genes on chromosome 13 affected by DNA 
copy number loss.  Re-sequencing analysis of the RB1 gene within this patient 
sample revealed only homozygous SNPs (Chapter 3) demonstrating 
isodisomy/gene conversion across all or part of chromosome 13. These data 
strongly suggest that chromosome 13 DNA copy number decreases in this 
patient (i.e. RB1 and/or NBEA loci) were selected for during disease 
development and likely contribute to MM biology.  
 
Because homozygous deletions of RB1 are rare in MM [15,32], we did consider 
the possibility that patient sample 95295 might be an outlier. This patient 
harbored the t(4;14) translocation, and had rapidly progressive disease 
characterized by treatment resistance (not shown).  If the 95295 sample is 
removed from our analysis, however, our conclusions remain substantially 
unchanged. Two distinct MDRs are still defined by the remaining interstitial 
deletions and identify a small number of candidate genes. At 13q13, NBEA 
remains the sole gene affected. Without sample 95295, the MDR at the gene-rich 
13q14.2 locus expands to include: SUCLA2, NUDT15, MED4, ITM2B, RB1, 
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P2RY5 and RCBTB2.  In bladder cancer it was found genes nearby to RB1 
(including ITM2B and P2RY5) contribute to disease [33]. Until further 
experiments are performed, we cannot formally exclude the possibility that 
additional 13q14.2 genes contribute to myeloma biology.  
 
Unsurprisingly, use of different window sizes within CBS analysis results in slight 
differences in chromosome breaks. We chose the 600bp window (avg. signal for 
ten probes in a row; probes spaced every ~60bp apart) since it provided clean 
segment breaks and mostly identified region consistent with visual analysis of the 
data. Both RB1 and NBEA were called by all analyses independent of window 
size. A 428Kb region 384Kb telomeric to RB1 within sample 95295 was not 
called by CBS with the 600bp window, but was called by the 1200 and 3000bp 
windows. This region affected the FNDC3A, MLNR, RAD17P2 and CDADC1 
genes. Whole genome aCGH performed on sample 95295, also detected this 
428Kb region (Figure 7) suggesting this is probably a true deletion. Even though 
these genes were affected by copy loss in patient sample 64511, RB1 and NBEA 
remain the only genes affected in three patient samples. None of those four 
genes were found in our microarray analysis of a large, independent patient set 
to be decreased in samples with monosomy 13 (Chapter 3).  
 
The region of copy number decrease detected in patient sample 64511 at 
13q14.2 (appears complex as the log2 ratios vary (Figure 4).  I-FISH analysis of 
this patient revealed potentially multiple clones as the copy number of RB1 was 
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complex (Table 2).  Almost 30 percent of the cells were null for both copies of 
RB1, 10.5% had three copies and 9.5% had four copies. Due to this finding, it is 
not surprising the aCGH results at this locus were varied and suggests this 
sample is comprised of multiple clones. 
 
Our aCGH identified the novel myeloma associated gene, NBEA that was 
affected by copy number decrease. NBEA spans 730Kb and encompasses the 
FRA13A fragile site [34]. Although common fragile sites are detected in normal 
cells, some fragile sites are prone to translocations or deletion and are thought to 
contribute to malignancy via alteration of expression of affected genes. For 
example, FRA3B (3p14.2) is involved in a translocation detected in renal cancer 
and affects the Fragile Histidine Triad (FHIT, FRA3B, AP3Aase) gene that likely 
functions as a tumor suppressor [35]. The breakpoints we observed were 
centromeric to the most fragile FRA13A breakpoint region in NBEA, suggesting 
that the NBEA deletion events we observed were not “bystander mutations” and 
suggest breaks within NBEA could have pro- tumor affects (Chapter 4). 
 
In addition to RB1 and NBEA, our data reveal a number of genes worth noting.  
Located on 13q34, CUL4A was a gene of interest in the context of our analysis, 
given previous reports [18] that identified it as a target in MM. CUL4A was not 
identified within the minimally deleted regions we describe here. This does not 
exclude a potential role for CUL4A in MM biology, as MM is a disease with 
diverse clinical presentations and complex genetics. Our analysis did identify 
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TFDP1 (DP1), also located at 13q34. DP1 is known to heterodimerize with E2F1 
[36] and therefore the RB1 pathway may be altered in those patient samples with 
TFDP1 deletions. The deletions affecting RB1 and TFDP1 were mutually 
exclusive; patient samples never harbored both, suggesting affecting two 
different genes in the same pathway could be leading to the same downstream 
effects. TFDP1 was not identified in our microarray analysis of genes 
downregulated in del 13 samples (Chapter 3). Further experiments are required 
to independently confirm the copy loss detected within TFDP1 and to address its 
potential functional contribution to myeloma biology.   
 
Finally, there has been a great deal of interest in the microRNAs known to exist 
on chromosome 13.  There are two miRNA clusters on chromosome 13. First, 
miR-15a and miR-16-1, located at 13q14.3 are deleted or downregulated in 
lymphocytic leukemia (CLL) patient samples [30]. These miRNA’s result in 
downregulation of the antiapoptotic molecule BCL2; therefore in patient samples 
with loss of miRNA-15a and miR-16-1 BCL2 is stabilized, leading to tumor cell 
survival [37]. The other miRNA cluster (miRNA-H1 miRNA-17, miRNA-18, 
miRNA-19a, miRNA-20, miRNA-19b-1 and miRNA-92-1) is located at 13q31.3 
and a recent report indicates this cluster is upregulated MM [36]. None of the 
deletions we identified overlapped either of these miRNA loci.  Our data suggest 
in our patient samples miRNA’s were not targeted by copy number decrease, 
although since identification of new miRNA’s and determining how they are 
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regulated is still ongoing, it remains a formal possibility they contribute to 
myeloma biology. 
 
Our data demonstrate for the first time recurring non-contiguous coordinate 
interstitial deletions affecting the RB1 and NBEA genes on chromosome 13 in 
myeloma.  Examination of larger patient groups will be required to validate the 
associations we observed, but our data support a multi-gene model to explain the 
biological effects of chromosome 13 deletions in myeloma. Loss of an entire 
chromosome might be the simplest mechanism for a myeloma cell to inactivate 
multiple genes at distinct loci, and provides an attractive explanation for the 
prevalence of whole chromosome 13 deletions in MM. Our data suggest 
compound heterozygosity of RB1 and NBEA may contribute to MM/MGUS 
biology.  
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Figure 1 
  
 
 
 
 
Figure 1. Purity of CD138 Selection from human bone marrow 
Shown is FACS analysis of whole bone marrow sample prior to CD138 selection 
(left) and after selection (right). Samples were stained with human PE-CD138 
antibody.  
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Figure 2 
 
 
 
 
 
Figure 2. Array CGH identifies DNA copy number loss on chromosome 13 
not detected by FISH or cytogenetics 
A. Whole chromosome 13 log2 plots of four patients with visually detectable 
chromosome 13 copy number loss (58762, 64511, 95295 and 68319).   B.  Pie 
chart summary of chromosome 13 abnormalities detected by cytogenetics, M-
FISH, I FISH and/or aCGH.   Eight patient samples harbored a chromosome 13 
abnormality detected by aCGH. Five of these appeared normal by cytogenetic 
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and FISH analysis. The number of patient samples is indicated in parentheses. 
C. Visual analysis of patients with interstitial deletions revealed by CBS analysis 
(black lines) within 23 to 50Mb (13q12-13q14.3) on chromosome 13.  Figure is to 
scale except for deletions smaller than 150Kb, which required scaling up to be 
visualized. Exact sizes of all segments shown are in Table 2. Cytogenetic data 
was used for whole chromosome 13-deletion information (gray lines).  Eight 
patient samples had coordinate copy number loss involving RB1 and NBEA (five 
patient samples with whole chromosome 13 deletion and three with interstitial 
deletions) highlighted by vertical rectangles. Patient sample 95295 harbored 
interstitial deletions affecting only RB1 and NBEA and defined the minimally 
deleted region across these eight samples. Patient sample 92896 had 
monosomy chromosome 13 by cytogenetics, but also a region of copy number 
loss indicated by black spot, suggesting homozygous deletion at that site.  
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Figure 3 
 
Figure 3. Significant chromosome 13 probes representing DNA copy 
number changes identified by Process Control. 
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A. Probes representing deleted and amplified regions in any of the 20 patient 
samples identified by Process Control Analysis. Data are plotted in a linear 
fashion across chromosome 13 beginning with the p arm to the left and 
extending throughout the long q arm to the right. 8844 probes marked regions of 
DNA copy number decrease and 6706 probes marked regions of DNA copy 
number increase. Arrowhead indicates region of copy number loss in 13q14. B. 
Process Control probes as in A detected in two or more patients. In two or more 
patient samples, 216 probes indicated DNA copy loss and 274 probes indicated 
DNA copy number gains. We found 69 of the 216 probes with DNA copy number 
decrease mapped to 42 genes (Table S2, Table 2).  
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Figure 4 
 
 
Figure 4. High-resolution aCGH and PCR analysis confirms RB1 is a target 
of recurrent interstitial deletions at 13q14.2  
 
A. Magnified view of DNA copy number losses located at 13q14.2. The smallest 
region of overlap across all three patients was defined by patient 95295, and 
mapped to exon 20 of RB1 (arrowhead). Locations of two genes in the region are 
shown for reference at the bottom. Each dot represents the average signal of ten 
consecutive probes.  Figure includes 1244 data points spanning 1.29Mb. The 
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region telomeric to RB1 within sample 95295 was not called by the 600bp CBS 
analysis, and therefore genes within that region are not listed in (Table 2; 
methods). That region was called by the analysis using different window sizes 
(1200bp or 300bp). Genes affected were FNDC3A, MLNR and CDAC1. Both 
RB1 and NBEA were called by all analyses independent of window size. B. PCR 
analysis confirms RB1 deletion within tumor sample of patient 95295. Germline 
skin DNA from patient sample 95295 (Skin: S), and an independent control 
sample (pooled DNA isolated from blood of four normal donors, Control: C), 
produced the expected full-length (4.4Kb) PCR product. In contrast, CD138 
purified tumor plasma cells from patient sample 95295 (Tumor: T) revealed a 
smaller PCR product (1.5Kb). Sequence analysis revealed the micro-deletion 
spanned 3486bp, which removed 2813bp of the 3’ end of intron 19, all of exon 20 
(146bp), and 527bp of the beginning of intron 20. In the middle of the sequencing 
product was a 435bp insertion with sequence identity to a region located 35Kb 
downstream of RB1 on chromosome 13 that did not map to any known gene, and 
was situated in the opposite orientation. The full-length 4.4Kb band was not 
detected in the tumor sample, suggesting a homozygous deletion. Water control 
is shown. Size in Kb is shown on left of gel image.  C. Real Time PCR analysis 
confirms RB1 copy number changes identified by aCGH. Control is patient 
54092, with no DNA copy number changes detected by aCGH, FISH, or 
cytogenetics (Table 1 and S1, data not shown). Error bars are SD of three 
experiments each performed in triplicate.  
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Figure 5 
 
 
 
Figure 5. The novel RB1 mutation, RB1del20 encodes a transcript resulting in  
 
expressed truncated protein 
 
A. Schematic of novel RB1 deletion in patient sample 95295 revealing deletions 
within intron 19, all of exon 20, and within intron 20. Numbers above lines 
represent length (bp) of retained sequences (and full length sequence in Normal, 
above). Gray box depicts insertion within deletion. B. Western Blot analysis of 
subcloned normal and mutated forms of RB1 in MSCV vector transiently 
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transfected into 293T cells. Truncated proteins run at predicted sizes (RB1 at 
110kDa and RB1del20 ~85kDa).  
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Figure 6 
 
 
Figure 6. NBEA is a target of recurrent interstitial deletions at 13q13  
A. Magnified view of overlapping region of DNA copy number loss across patient 
samples 58762, 64511 and 95295. The only gene identified within this region is 
NBEA. The region of DNA copy number decrease within patient 64511 spanned 
885Kb mapping to exon 1-9 of NBEA. Within patient 95295, the region spanned 
107Kb mapping to NBEA exons 3-19. Each dot represents the average signal of 
10 consecutive probes as in Figure 2. Plots include 950 data points spanning a 
region of 0.998Mb. In patient samples 58762 and 64511 there appears to be a 
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small region with DNA copy increase. Examination of the raw data within this 
region from the reference sample (skin) from all 20 patients revealed the average 
of these probes was below 10,000, suggesting this is not an array artifact and 
was also flagged by CBS algorithm. B. Real time PCR confirms DNA copy 
number loss within NBEA. Control is patient 54092, with no DNA copy number 
changes detected by aCGH, FISH, or cytogenetics (Table 1 and S1, data not 
shown). Error bars are SD of two experiments performed in triplicate. 
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Figure 7 
 
 
 
 
 
Figure 7. Whole genome aCGH analysis of patient sample 95295 reveals 
similar regions of copy number loss found in chromosome 13- focused 
array 
Whole genome aCGH (Nimblegen, median probe spacing 1.1Kb) was performed 
on DNA isolated from patient sample 95295. The data from chromosome 13 is 
shown.  
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Chapter 3 
 
Characterization of Retinoblastoma (RB1) in 
Multiple Myeloma 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Published in part as:  
O’Neal, et al.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions 
at 13q13 in patients with MGUS and multiple myeloma. Exp. Hem. 2009; 37:234-
44. 
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3.1 Abstract 
 
We identified RB1 as part of a minimally deleted region on chromosome 13 
affected by copy loss in myeloma, and therefore set out to characterize RB1 
mutation status and expression in myeloma primary samples and cell lines. Re-
sequencing analysis of all 27 RB1 exons on DNA purified from CD138 selected 
cells from 41 primary patient samples revealed no exonic mutations, suggesting 
retained RB1 alleles in myeloma are wild type. We examined whether patient 
samples and myeloma cell lines with monosomy 13 expressed reduced levels of 
RB1 transcripts or protein, respectively, and found lower RB1 transcripts and 
protein in cells with monosomy chromosome 13.  Since RB1 can be inactivated 
by phosphorylation, we sought to determine whether RB1 protein was 
phosphorylated in MM. We found RB1 was phosphorylated in MM cell lines, but 
RB1 phosphorylation was rare in primary patient samples. Together, our data 
suggest a model whereby wild type RB1 protein is expressed at lower dose in 
samples with monosomy 13, and becomes phosphorylated late in 
myelomagenesis.  
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3.2 Introduction 
 
3.2A RB1 is a tumor suppressor gene regulated by phosphorylation 
RB1 was the first identified tumor suppressor gene, and is highly studied, as 
disabling the “RB1 pathway” is believed to be essential for virtually all tumor 
formation [1]. Mutations in, or deletions of, both copies of RB1 in the retina are 
causative for development of retinoblastoma tumors in humans. Studies of DNA 
isolated from retinoblastoma patients led to Knudson’s famous “two hit” model of 
tumor suppressor genes. Knudson observed patients with inherited 
predisposition to retinoblastoma and correctly predicted that one defective RB1 
allele was inherited, and the other was somatically mutated, ultimately leading to 
inactivation of both copies of the gene [2]. 
 
RB1 is a nuclear phosphoprotein that functions in multiple cellular processes 
including cell cycle, apoptosis, differentiation, and senescence. It’s most well 
studied function is to inhibit the cell cycle, which is regulated by phosphorylation. 
Hypo-phosphorylated is the “active” form of RB1 that represses transcription of 
cell cycle-promoting genes in two ways. First, RB1 can directly to bind to the 
transactivation domain of the E2F transcription factor [3,4] Second, while 
RB1/E2F complexes bind DNA, RB1 can recruit chromatin remodeling enzymes 
that downregulate gene expression [5-8]. Both events prevent transcription of 
E2F targets including genes required for replication, DNA metabolism and 
synthesis, cyclin E, and cyclin A [9,10].  
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RB1 has 16 serine/threonine phosphorylation sites whose phosphorylation status 
changes throughout cell cycle. RB1 gets partially phosphorylated during the cell 
cycle by cyclin dependent kinase (CDK, CDK4/CDK6) - Cyclin D (and then E) 
complexes.  CDK’s require cyclins for active kinase activity. There are two 
protein families that act to inhibit cyclin/CDK complexes from phosphorylating 
RB1. First, the INK family (P16INK4a, P15INK4b, P18Ink4C, P19Ink4D) can specifically 
block the kinase activity of CDKs.  Second, the “Cip/Kip” family (p27KIP1, P21CIP1 
and p57Kip2) can bind to and sequester cyclins from CDKs. Both of these 
negative regulators, when intact, prevent phosphorylation (and therefore 
inactivation) of RB1. Together, these proteins comprise the “RB1 pathway”. 
 
Inactivation of RB1 pathway occurs via mutation, deletion, methylation, or 
phosphorylation  
Inactivation of the RB1 pathway occurs in different ways in a different tumor 
types.  Deletion or mutation of RB1 is found in retinoblastoma, breast, bone, 
brain, bladder, and some lung cancers. However, genetic inactivation of RB1 is 
not universal to all cancers, including those with heterozygous RB1 mutations 
[10]. In many tumors, the remaining RB1 is inactivated post-translationally by 
phosphorylation.  This occurs via deletion, mutation or methylation of the INK4a 
locus (CDKN2A) affecting p16. Alternatively, over-expression of Cyclin D, (which 
can activate CDK4/6) also results in hyper-phosphorylated RB1. Together, 
multiple mechanisms inactivate RB1. 
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We identified RB1 as being part of a minimally deleted region in plasma cell 
dyscrasias, and therefore sought to further characterize RB1 in myeloma. Our 
aCGH, cytogenetic, and FISH analysis of chromosome 13 in primary patient 
samples revealed that samples with deletions affecting one copy of RB1, 
retained the remaining allele (except for sample 95295, that harbored a 
homozygous mutation), in MGUS and MM (Chapter 2). We examined whether 
patient samples and myeloma cell lines with monosomy 13 expressed reduced 
levels of RB1 transcripts or protein, respectively, and found lower RB1 transcripts 
in primary patient samples and protein in cell lines with monosomy chromosome 
13. To determine if RB1 is inactivated in MM via mutation, we performed 
comprehensive re-sequencing of RB1 in 41 primary patient samples and found 
inactivating mutations of RB1 to be a very rare event in myeloma. 
Immunohistochemistry and Western blot analysis on primary patient samples and 
MM cell lines, respectively, revealed RB1 was phosphorylated in MM cell lines, 
but not primary patient samples, suggesting phosphorylation of RB1 is a late 
event in myeloma.  
 
 
 
 
 
 
 
 76 
 
3.3 Methods 
Large-scale sequencing of RB1 in primary human samples 
High-throughput sequence analysis of RB1 was performed by the Genome 
Sequencing Center at Washington University (WUSTL) as described [11] 
Detailed protocols are available on WUSM GSC website 
(http://genome.wustl.edu/platforms.cgi?id=7). PCR validation of RB1 SNPs was 
performed on genomic DNA isolated from CD138+ selected bone marrow (tumor) 
and skin biopsy (normal) patient samples. The independent control DNA was 
kindly provided by Rhonda Reis, Division of Oncology, WUSTL. Products were 
cloned into and sequenced from TOPO2.1 vector (Invitrogen, Carlsbad, CA).  
 
Microarray Expression Analysis 
Two independent microarray datasets were analyzed. First, a Mayo Clinic 
dataset [12] included 162 samples (101 MM, 24 SMM, 22 MGUS, and 15 normal 
PC’s; GEO GSE6477; chromosome 13 status was determined by FISH). Second, 
we used a multiple myeloma research consortium (http://www.themmrc.org; 
MMRC) dataset that included 100 MM samples (Chromosome 13 status was 
determined by aCGH).  
 
Expression values were derived against a PM/MM difference background using 
Robust Multichip Average (RMA) [13]. Present/Absent probes were called using 
Affymetrix Microarray Suite version 5. Only probes detected in at least one 
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sample were used in subsequent comparisons. In pooled Chromosome 13 
Deletion versus no Deletion comparisons, Significance Analysis of Microarrays 
(SAM), [14] was used to detect differentially expressed genes based on a q-value 
of less than 5%. SAM was run with 100 permutations for correction of False 
Discovery Rate. These genes were clustered and visualized in DChip [15] 
(http://www.dchip.org). aCGH data was first smoothed with region=2, outlier 
scale =4, smoothing SD=2 and trimming proportion of 0.025. CBS was then run 
with default parameters (alpha=0.01, window.size= NULL, with 10000 
permutations). 
 
Western blot and cell lines 
LP-1, KMS-11, OPM-2 and UTMC2 lines were provided by W. Michael Kuehl, 
(Genetics Branch, NIH) and maintained in RPMI with 1% Penicillin/Streptomycin 
(both Cambrex Bioscience, Walkersville, MD), 10% fetal bovine serum  
(HyClone, Logan, Utah). RPMI-8226, U266, and H929 cells were obtained from 
and grown per ATCC recommendations. Lysates were prepared as described 
[16] Antibodies: total RB1: IF8 (Santa Cruz Biotechnologies, Santa Cruz, CA); 
anti-phospho-RB1(Serine Ser807/811; Cell Signaling, Beverly, MA); Actin 
(Sigma, St. Louis, MO). 
 
FACS analysis 
One million cells/sample were permeabilized and fixed using the protocol in the 
BRDU kit (BD Pharmingen, San Diego, CA), since this method was found to be 
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amenable to adaptation for our intracellular RB1 staining. Prior to antibody 
staining, a block step was added to prevent non-specific antibody binding (20 
minute incubation of cells in PBS with 2.5g/500mL Bovine Serum Albumin; 
Sigma-Aldrich, St. Louis, MO). Cells were stained with same phospho- Ser 
807/811 antibody used in Western Analysis.  
 
Immunohistochemical staining of RB1 in primary samples 
This analysis was performed per standard techniques in clinical pathology lab at 
Washington University. Antibodies: total RB1 antibody (4H1, Cell Signaling, 
Boston, MA); phospho-Serine 807/811 antibody used in Western and FACS 
analysis was used for this analysis. Samples were scored blind for generation of 
semi-quantitative analysis.  
 
Analysis of murine hematopoeisis 
Rb1 WT (n=4) and HET (n=6) mice were provided by Katherine Wikenheiser 
(Dept. of Pathology, University of Cincinnati) initially generated by Tyler Jacks 
[17]. These were provided to us as fifth generation C57BLACK/6 X129 mix. We 
performed backcrossing to  C57BLACK/6 generation ten. Two and a half month 
old mice were analyzed. Mice were injected i.p. with 200ml 10%w/v SRBC or 
PBS (generation five mice- all other experiments-generation ten) and analyzed 
mice seven days post treatment. FACS analysis and blood counts were 
performed as described previously [18]. 
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3.4 Results 
3.4A Retained RB1 alleles in MGUS/MM patient samples are mostly wild 
type  
Our data suggested one copy of RB1 is a target of deletions in MM, yet in most 
patient samples (7/8 in our set) the other copy is retained. Limited sequence 
analysis in myeloma has failed to show mutations in RB1 exons 20-24 [19] 
(mutation hotspots in retinoblastoma) [20, 21] but other domains of RB1 have not 
been re-sequenced in MM. We therefore performed comprehensive sequencing 
of all 27 RB1 exons and surrounding intronic sequences in 41 MM/MGUS patient 
samples (including 16 of our 20 patient set; Table 1). We found no non-
synonymous sequence changes affecting the coding or promoter sequences (bp 
-474 to -182) of RB1, suggesting that, in contrast to retinoblastoma tumors, most 
myeloma tumors retain at least one wild-type RB1 allele.   
We detected eleven intronic SNPs (Table 1).  Since myeloma is twice as 
prevalent in African American populations compared to Caucasians 
(www.seer.cancer.gov), race matched minor allele frequencies (MAFs) from our 
patient samples were compared to published MAFs in the Hap Map database for 
the nine of eleven SNPs with available data (Table 2). Two RB1 SNPs (rs198580 
and rs198617) were significantly more common in our Caucasian patients (P < 
0.001 and P < 0.018, respectively), suggesting a possible role in MM 
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pathogenesis. No significant differences were found between subgroups for the 
other seven SNPs.  
We identified six novel SNPs, not reported in the NCBI or HapMap databases 
(Table 3).  To confirm this result, DNA from tumor samples with novel SNPs 
were used for PCR and subsequent sequence analysis. To determine whether 
these were tumor-associated changes, the matched skin samples were 
subjected to the same analysis. The novel SNPs were confirmed, and all were 
found to be present in both tumor and matched skin genomic DNA, 
demonstrating these to not be tumor associated and instead normal sequence 
variants. Since both the known and novel SNPs were located near exon 
boundaries (range: 10-171bp from the start or end of an exon), we considered 
the possibility that RB1 SNPs might play a role in MM pathogenesis by affecting 
RNA splicing. Examination of RB1 cDNA isolated from seven patients with 
reported or novel SNPs revealed only RB1 transcripts of expected size (not 
shown). Together, our re-sequencing analysis demonstrated no somatic 
mutations affecting RB1 in the retained allele. 
 
 
 
3.4B RB1 protein is decreased in MM cell lines with monosomy 13  
Even in the setting of chromosome 13 deletions, RB1 transcripts are abundant in 
MM cells, consistent with the finding that epigenetic silencing of the RB1 
promoter does not occur in MM [22]. To determine whether RB1 protein levels 
were related to chromosome 13 copy number, we performed Western Blot 
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analysis on a panel of MM cell lines with known genetic copy number of the RB1 
locus.  RB1 protein was detected in all cell lines that retained at least one RB1 
allele (Figure 1). U266, shown to have undergone rare biallelic loss of RB1  [23] 
involving deletion of exon 13 and 14 [24] expressed no RB1 protein as expected, 
as did UTMC2 cells (Figure 1).  LP-1 and KMS-11 cells, which retain only one 
copy of chromosome 13, [23] expressed lower levels of RB1 protein than OPM-2 
and RPMI-8226 cells, which retain two copies of the RB1 locus [23]. These data 
suggest RB1 protein levels were related to RB1 genomic copy number in 
myeloma cell lines.  
To further confirm this result, we performed FACS analysis to examine RB1 
protein levels on a per-cell basis.  Consistent with the Western Blot analysis, we 
found cell lines with two copies of RB1 (OPM2) had higher protein than those 
cells with one genomic copy of RB1 (LP-1; Figure 1).   
3.4C RB1 transcripts are decreased in primary patient samples with 
monosomy 13 
Our cell line data implied RB1 protein levels were related to genomic copy 
number. We hypothesized RB1 transcript levels would be decreased in primary 
patient samples with monosomy chromosome 13.  Since our data set was 
relatively small, examined a large patient data set that included patient samples 
with and without monosomy 13.  We analyzed two published data sets 
comprising 162 (101 MM, 24SMM, 22 MGUS, and 15 normal PC’s; Mayo GSE 
6477; [11] and 100 (MMRC) patient samples (methods) and compared RB1 
 82 
transcript levels between patient samples with our without monoallelic deletion of 
chromosome 13. In both datasets, RB1 transcript levels were decreased in 
patient samples with monosomy 13 (Table 4; Mayo: -0.69 Fold Change; MMRC  
-0.67 Fold Change). These data suggested in the majority of patient samples, 
RB1 transcript levels were decreased in samples harboring copy number loss of 
chromosome 13, consistent with prior reports [25-27]. 
 
 
3.4D Rb1 heterozygous mice have normal hematopoeisis 
Although at odds with RB1’s canonical tumor suppressor role, our RB1 
expression data above prompted us to consider a model of RB1 
haploinsufficiency, whereby half RB1 protein dose alters the B cell compartment 
to contribute to MM pathogenesis. To this end, we examined hematopoietic 
compartments of Rb1 heterozygous mice (Rb1+/-; [17] compared to wild type 
(Rb1+/+) littermates. We found similar absolute spleen weights (Rb1+/+: average 
0.067g, SD: 0.005, n=4; Rb1+/-: average 0.064g, SD 0.008, n=6) and peripheral 
blood counts (Rb1+/+: 5.80k/µl, SD 2.02, n=4; Rb1+/-: 8.74k/µl, SD 4.40, n=6) in 
both groups of mice. We found similar distributions of B cells (B220), myeloid 
cells (GR-1/MAC1), and T cells (CD4, CD8) isolated from bone marrow and 
spleen mononuclear cells at baseline (Figure 2).  
 
To determine whether haploinsufficiency of Rb1 affects the B cell compartment in 
stress conditions, wild type and heterozygous mice were inoculated with sheep 
red blood cells, known to induce germinal center (GC) reactions [28]. Spleen 
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weights and plasma cell percentages increased in all mice independent of 
genotype to similar levels cells (Figure 2, not shown), suggesting GC reactions 
formed independent of Rb1 genotype. Together, these data fail to support a role 
of RB1 haploinsufficiency as the single genetic abnormality in MM pathogenesis, 
and suggests additional events cooperate with RB1 deletions in myeloma 
pathogenesis.  
 
 
3.4E RB1 protein is phosphorylated in MM cell lines, but is rarely 
phosphoryated in primary patient samples 
Since we did not find RB1 mutations in this study, we hypothesized RB1 would 
be inactivated by phosphorylation in MM.  Western Blot analysis was performed 
on the same MM cell line panel as above using an antibody that recognizes only 
phosphorylated RB1 protein (Ser807/811). All MM lines that retained at least one 
copy of RB1, expressed phosphorylated RB1 protein (Figure 1) consistent with a 
previous analysis [29]. Levels of phosphorylated RB1 protein, as with total RB1 
protein above, were more abundant in cells with two RB1 alleles compared to 
those with one. These data show RB1 protein is phosphorylated MM cell lines.  
Since MM cell lines are isolated from plasmacytomas, (extramedullary, late stage 
myeloma), we wanted to determine whether RB1 protein was phosphorylated in 
primary patient samples. To address this, we performed immunohistochemical 
staining of a set of 25 primary patient samples (1 MGUS, 1SMM, 22MM, and 1 
PCL) using two RB1 antibodies (Figure 3, Table 5). First, we used an antibody 
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(4H1) that recognizes RB1 protein independent of phosphorylation status. The 
second antibody recognizes only phosphorylated RB1 protein (Serine 807/811). 
As expected, total RB1 protein was found in most patient samples using the 
antibody that binds to RB1 independent of phosphorylation status. To our 
surprise, we found very little to no phosphorylated RB1 in most patient samples, 
independent of disease stage. These data suggest a model whereby RB1 protein 
is phosphorylated only very late in myeloma development.  
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3.5 Discussion 
Mutation of RB1 is rare in Myeloma 
The RB1 tumor suppressor has a long and famous history, as it was the first 
identified tumor suppressor gene and the basis for Knudsen’s model of tumor 
suppressor genes originally worked out by examining RB1 in retinoblastoma 
patients [2]. In myeloma, RB1 has gained much attention since it is a recurrent 
site of deletion and in fact, the RB1 locus is commonly used as the probe in 
clinical FISH analysis to examine chromosome 13 deletions. Our aCGH analysis 
revealed RB1 was the sole gene affected in a minimally deleted region at13q14.2 
(Chapter 2).  
 
We hypothesized retained RB1 alleles would be mutated in myeloma. We 
performed large- scale exonic sequencing of RB1 on 41 primary CD138 purified 
patient sample DNAs, but did not detect mutations affecting RB1 exons. The only 
tumor-associated RB1 exonic mutation we identified was found by aCGH, and 
not this sequence analysis (Chapter 2). The deletion was not identified by large-
scale sequencing approach because of the small amplicon size, which was 
entirely deleted in patient sample 95295.  The wild type RB1 sequence in sample 
95295 was likely amplified from the WT RB1 allele present in residual normal 
plasma cells. Overall, our sequence analysis revealed retained RB1 alleles are 
essentially unaffected by exonic mutation in myeloma. This suggests that if 
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inactivation of RB1 is relevant to MM pathogenesis, it occurs via a different 
mechanism than mutation of the RB1 coding sequence.  
 
Inactivation of “RB1 pathway” in myeloma remains controversial and 
largely unconvincing 
There are multiple ways tumor cells can inactivate the “RB1 pathway” ultimately 
leading to phosphorylated and inactive RB1 protein unable to regulated cell 
cycle. Methylation of the CDKN2A locus (encoding P16INK4A and P19ARF) results 
in reduced to no expression of P16, leading to downstream activation of 
cyclin/CDK complexes and subsequent RB1 phoshorylation. Methylation of 
CDKN2A is detected in 23-53% of myeloma patient samples. [22,30-32]. 
However, most studies report lack of P16 downregulation in samples with 
CDKN2A [32,33]. P16 methylation is not related to plasma cell labeling index 
[32], patient or progression- free survival [30, 32]. P15 methylation is detected in 
17-35% of MM samples, but RB1, P18 and P14 were not [22,30]. Methylation of 
genes within the “CIP/KIP” family is rare [33]. Although methylation of some 
genes within the RB1 pathway is detected in MM, levels may be insufficient to 
sufficiently downregulate gene expression. Together, there is lack of convincing 
evidence that methylation of INK4 and CIP/KIP loci contribute to MM. 
 
Up-regulation of Cyclin 1, 2, or 3 is reported to be universal in myeloma [34] via 
the (11;14)(q13;32) translocation, trisomy 11, translocations affecting genes that 
positively regulate cyclin D2 (c-MAF via the t(14;16)(q32;q23), or by as yet 
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undetermined mechanisms. These predict Cyclin D accumulation, formation of 
Cyclin D-CDK4/6 complexes, phosphorylation (and inactivation) of RB1, and 
increased cell cycle due to inactivation of RB1 via phosphorylation. However, 
multiple lines of evidence lead to the conclusion that the expression of cyclin D 
does not lead to myeloma cell growth via increased proliferation. Paradoxically, 
the presence of the t(11;14)(q13;32) translocation confers good prognosis [35] as 
does detection of cyclin D1 expression [36]. Proliferation rates (BRDU) in 
t(11;14)+ myeloma cells revealed lower proliferative index than other myeloma 
samples [37,38]. Finally, in primary MM samples, expression of cyclin D1 or D3 
was insufficient to promote RB1 phosphorylation, and levels of cyclin D1 were 
unrelated to MM cell proliferation [29]. Levels of CDK4/6 in cells expressing 
Cyclin D may be too low to fully inactivate RB1 [29, 39]. Our own analysis 
revealed phosphorylation of RB1 was rare in primary patient samples. Together, 
these data suggest the contribution of RB1 protein to MM is not via the 
“canonical RB1 inactivation” pathway. 
 
RB1 haploinsufficiency may contribute to MM via non-traditional  
mechanisms 
Our analysis of RB1 protein in MM cell lines, and RB1 transcripts in primary 
patient samples, revealed levels of RB1 were related to RB1 genetic copy 
number. In other words, we observed RB1 levels were lower in cells with single 
RB1 deletion compared to cells that retained two alleles, consistent with prior 
reports [25-26] and verified with Q- RT-PCR analysis [27]. Protein analysis via 
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Western Blot analysis has largely been limited by insufficient sample quantity. 
We were unsuccessful in our efforts to examine a panel of primary patient 
samples, however it is a future goal of the lab to extend our FACS assay on 
primary samples.  
 
Because we, and others [25-27] found RB1 levels correlated with genomic RB1 
copy number, we seriously considered the possibility RB1 haploinsufficiency 
alone might contribute to myeloma. The Drosophila homologue of the 
RB1/Rb1gene family, Rbf, has a haploinsufficient phenotype in a genetic model 
of eye tumors [40]. Many tumor suppressors including, for example, the CIP/KIP 
family member p27kip1 display haploinsufficient phenotypes in mice, whereby 
heterozygous mice expressing wild type protein at reduced dose display cancer 
prone phenotypes [41]. 
 
However, much data supports the conclusion that RB1 haploinsufficiency alone 
does not appear to contribute to malignancy in humans and mice. No myeloma 
related phenotype has been reported in long-term follow up of surviving 
retinoblastoma patients with germline inactivating RB1 mutations [42]. Loss of 
one copy of RB1 as a sole abnormality is not prognostic for reduced patient 
survival in myeloma [43].  Rb1+/- mice develop tumors only after loss of the 
remaining Rb1 allele [17] and when Eµ-Myc mice (known to develop B cell 
neoplasms), are mated to Rb1+/+ or Rb1+/- mice, no survival differences are 
observed [44].  
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Our analysis of 8-9 week old Rb1+/+ versus Rb1+/- mice (backcrossed to 
generation 10 C57BL/6) revealed no differences in basal hematopoeisis or 
plasma cells development upon antigen stimulation, consistent with another 
report [45]. However, in Rb1 null retina cells, the Rb1 family member, p107 
compensates for Rb1 [46,47]. In hematopoeisis, p107 sometimes, [45] but not 
always, [48] compensates for loss of Rb1. To avoid the issue of p107 
compensation completely, generation of mice with conditional deletion of Rb1 in 
plasma cells in the context of p107-/- is necessary. We are currently mating 
Rb1flox/flox [49] mice to mice expressing Cre recombinase under the control of the 
Cγ1 heavy chain isotype whose transcription is induced in germinal centers upon 
stimulation with T cell dependent antigens [50] to generate mice with Rb1 
deletions in germinal center B cells. These mice will be mated to p107-/- mice to 
generate Cγ1CreRb1+/+p107-/- and Cγ1CreRb1Flox/+p107-/- mice. If 
haploinsufficiency of Rb1 is sufficient to contribute to myelomagenesis, then we 
predict to see tumor or MGUS phenotypes in the Cγ1CreRb1Flox/+p107-/- mice but 
not in the Cγ1CreRb1+/+p107-/- mice.   
 
Myeloma cells follow an observation made in solid tumors: RB1+ tumors tend to 
be slow-growing, chemotherapy resistant, and have little spontaneous apoptosis, 
whereas RB1- tumors proliferate fast, are chemotherapy sensitive, and have high 
rates of spontaneous apoptosis [51].  Heterozygous loss of RB1 is detected in 
MGUS and MM, suggesting it is an “early” event in PC dyscrasias. Retention of 
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expressed, half dose RB1 protein could be selected for in MGUS or MM cells due 
to its ability to inhibit apoptosis. Although paradoxical, that RB1 can prevent 
apoptosis, (a pro-tumor event opposite its well-described tumor suppressor 
function), this actually makes sense since during much of myeloma, cell cycle 
occurs at a low rate and these cells are able to evade apoptosis. Myeloma cells 
heterozygous for RB1 may express sufficient protein to sequester enough E2F to 
prevent complete dysregulation of cell cycle, and also inhibit 
activation/transcription of the E2F mediated apoptotic pathway including P73 (a 
P53 family member). Analysis of P73 expression could address this possibility, 
and would be predicted to be low. RB1 mediated inhibition of apoptosis could 
occur via an E2F independent mechanism via its association with Abl or Jnk 
kinases, known to inhibit apoptosis [52]. Immunoprecipitation experiments could 
experimentally address this possibility. Alternatively, RB1 can regulate 
senescence and differentiation [53]. Haploinsufficiecy of RB1 in myeloma cells 
may result in a reduced ability to drive these cells to senescence. Together, it 
remains a testable hypothesis, that via alternative mechanisms than in other 
tumor types, haploinsufficiency of RB1 contributes to MGUS and MM.  
 
Although RB1 is the subject of over 1400 research articles, there is still much to 
learn. The “binary switch” model whereby hyper-phosphorylated RB1 is inactive 
and unable to prevent cell cycle, and hypo-phosphorylated RB1 is active is too 
simple [54]. It is likely differential phosphorylation of the 16 serine/threonine sites 
in RB1 affects it ability to regulate its other functions including differentiation, 
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prevention of apoptosis, and senescence. For example, Serine 567 does not get 
phosphorylated during regular cell cycle; however when phosphorylated, RB1 
protein becomes destabilized and cell death occurs [55]. Cell type specific 
phospho peptide mapping may elucidate which sites are phosphorylated in early 
B cells, MGUS and MM cells and provide insight to which phosphorylated 
residues regulate different the RB1 effector functions discussed above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 92 
 
 
 
3.6 Acknowledgements 
 
The data from this chapter would not have been possible without a lot of help. 
First, the Washington University Genome Sequencing Center is responsible for 
helping us obtain the sequence analysis. Yumi Kasi was instrumental in this 
effort. Anjum Hassan and the Clinical Pathology lab generated the IHC data, 
which has also been a lot of work, but provided insights we would not have 
otherwise had. Punit Vachharajani and Yuron (Mack) Su were both outstanding 
STARS students I was fortunate to work with. They both put in a lot of effort to 
get the phospho-flow analysis up, running, and to the point that it may actually be 
feasible to look at primary patient samples with this labor-intense technique. 
Rachel Delston in Bill Harbour’s lab has been a wonderful “RB1 friend” and she 
has really given me a lot of advice and tools to enable studies of RB1.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 93 
 
 
 
3.7 References 
1. Sherr CJ and McCormick F The RB and P53 pathways in cancer. Cancer Cell. 
2002; 2:103-112. 
 
2. Knudson AG. Mutation and cancer: Statistical study of retinoblastoma. PNAS. 
1971; 68: 820–23. 
 
3. Flemington EK, Speck SH, and Kaelin WJ. E2F-1-mediated transactivation is 
inhibited by complex formation with the retinoblastoma susceptibility gene 
product. PNAS. 1993; 90: 6914-18. 
 
4. Helin K, Wu C, Fattaey AR, et al. Heterodimerization of the transcription 
factors E2F-1 and DP-1 leads to cooperative trans-activation. MCB. 1993; 7: 
1850-61. 
 
5. Weintraub SJ, Chow KNB, Luo RX et al. Mechanisn of active transcriptional 
repression by the retinoblastoma protein. Nature. 1995; 375: 812-15.   
 
6. Sellers  WR, Rodgers JW and Kaelin WG. A potent transrepression domain in 
the retinoblastoma protein induces a cell cycle arrest when bound to E2F sites. 
PNAS.1995; 92: 11544-48. 
 
7. Bremner  R, Cohen BL, Sopta M et al. Direct Transcriptional repression by 
pRB and its reversal by specific cyclins. MCB. 1995; 15: 3256-65.  
 
8. Adnane J, Shao Z, and Robbins PD. The retinoblastoma susceptibility gene 
product represses transcription when directly bound to the promoter. JBC. 1995; 
270: 8837-43. 
 
9. Johnson DG. Schwartz JK, Cress WD. et al. Expression of transcription factor 
E2F1 induces quiescent cells to enter S phase. Nature. 1993; 365: 349-52.  
 
10. Horowitz JM, Park SH, Bogenmann E, et al. Frequent inactivation of the 
retinoblastoma anti-oncogene is restricted to a subset of human tumor cells. 
PNAS. 1990; 87: 2775-79.). 
 
11. Link DC, Kunter G, Kasai Y, et al. Distinct patterns of mutations occurring in 
de novo AML versus AML arising in the setting of severe congenital neutropenia. 
Blood. 2007;110:1648-1655. 
 
12. Chng WJ, Kumar, S, Van Wier S et al. Molecular dissection of hyperdiploid 
multiple myeloma by gene expression profiling. Cancer Research. 2007; 67: 
2982-89. 
 94 
 
13. Bolstad, BM, Irizarry RA, Astrand, M, et al. A Comparison of Normalization 
Methods for High Density Oligonucleotide Array Data Based on Bias and 
Variance. Bioinformatics. 2003 19(2):185-193. 
 
14. Tusher, VG, Tibshirani, R & Chu, G. Significance analysis of microarrays 
applied to the ionizing radiation response .PNAS USA 2001; 98: 5116–5121 
 
15. Li C, and Wong, WH. Model-based analysis of oligonucleotide arrays: 
Expression index computation and outlier detection. PNAS USA. 2001; 98: 31-
36. 
 
16.  Xiang Z, Kreisel F, Cain J, Colson A, Tomasson MH. Neoplasia driven by 
mutant c-KIT is mediated by intracellular, not plasma membrane, receptor 
signaling. Mol Cell Biol. 2007;27:267-282. 
 
17. Jacks T, Fazeli A, Schmitt EM, Bronson RT, Goodell MA, Weinberg RA. 
Effects of an Rb mutation in the mouse. Nature. 1992;359:295-300. 
 
18. Cain JA, Xiang Z, O'Neal J, et al. Myeloproliferative disease induced by TEL-
PDGFRβ displays dynamic range sensitivity to Stat5 gene dosage. Blood. 
2007;109:3906-3914. 
 
19. Zandecki M, Facon T, Preudhomme C, et al. The retinoblastoma gene (RB-1) 
status in multiple myeloma: a report on 35 cases. Leukemia and Lymphoma. 
1995; 18: 497-503. 
 
20. Valverde JR, Alonso J, Palacios I, Pestana A. RB1 gene mutation up-date, a 
meta-analysis based on 932 reported mutations available in a searchable 
database. BMC Genet. 2005;6:53.  
 
21. Nichols KE, Houseknecht MD, Godmilow L, et al. Sensitive multistep clinical 
molecular screening of 180 unrelated individuals with retinoblastoma detects 36 
novel mutations in the RB1 gene. Hum Mutat. 2005;25:566-574. 
 
22. Chim CS, Fung TK and Liang, R. Disruption of INK4/CDK/RB cell cycle 
pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia. 
2003; 17: 2533-35. 
 
23. Juge-Morineau N, Mellerin MP, Francois S, et al. High incidence of deletions 
but infrequent inactivation of the retinoblastoma gene in human myeloma cells. 
Br J Haematol. 1995;91:664-667. 
 95 
24. Corradini P, Inghirami G, Astolfi, M et al. Inactivation of Tumor suppressor 
genes, p53 and RB1 in Plasma Cell Dyscrasias. Leukemia; 8: 758-67.  
 
25.  Carrasco DR, Tonon G, Huang Y, et al. High-resolution genomic profiles 
define distinct clinico-pathogenetic subgroups of multiple myeloma patients. 
Cancer Cell. 2006; 9: 313-325. 
 
26. Shaughnessy J, Jacoboson J, Sawyer J, et al. Continuous absence of 
metaphase defined cytogenetic abnormalitiies, especially of chromosome 13 and 
hypodiploidy, ensures long-term survival in multiple myeloma treated with Total 
Therapy I: Interpretation in the context of global gene expression. Blood. 2003; 
101: 3849-56. 
 
27.  Agnelli L, Bicciato, S, Fabris S, et al. Integrative genomic analysis reveals 
distinct transcriptional and genetic features associated with chromosome 13 
deletion in multiple myeloma. Haematologica. 2007; 92: 56-65. 
 
28. Shinall SM, Gonzalez-Fernandez M, Noelle RJ, Waldschmidt TJ. 
Identification of murine germinal center B cell subsets defined by the expression 
of surface isotypes and differentiation antigens. J Immunol. 2000;164:5729-5738. 
 
29. Ely S, Di Liberto M, Niesvizky R, et al. Mutually exclusive cyclin-dependent 
kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates 
retinoblastoma protein and promotes cell cycle dysregulation in multiple 
myeloma. Cancer Res. 2005; 65:11345-11353. 
 
 
30. Martin P, Garcia-Cosio M, Santon A et al. Aberrant gene promoter 
methylation in plasma cell dyscrasias. Experimental and Molecular Pathology. 
84; 2008: 256-61. 
 
31. Dib A, Barlogie B, Shaughnessy J et al. Methylation and expression of the 
p16INK4A tumor suppressor gene in multiple myeloma. Blood. 109; 2007: 1337-
38. 
 
32. Gonzalez-paz, chng WJ, McClure RF et al. Tumor suppressor p16 
methylation in multiple myeloma:biological and clinical implications. Blood. 2006; 
109: 1228-32. 
 
33. Chim CS, Liang R, Fung TK et al.  Infrequent epigenetic dysregulation of 
CIP/KIP family of cyclin-dependent kinase inhibitors in multiple myeloma. 
Leukemia. 2005; 19: 2352–55. 
 96 
34. Bergsagel PL, and Juehl WM. Critical roles for immunoglobulin translocations 
and cyclin D regulation in multiple myeloma. Immunological Reviews. 2003; 194: 
96-104. 
 
35. Fonseca R., Barlogie B., Bataille R. et al Genetics and Cytogenetics of 
Multiple Myeloma: A Workshop Report. Cancer Research. 2004;  64: 1546-1558. 
 
36. Soverini S, Cavo M, Cellini L et al. Cyclin D overexpression is a favorable 
prognostic variable for newly diagnosed multiple myeloma patients treated with 
high dose chemotherapy and single or double autologous transplantation. Blood. 
2003; 102: 1588-94. 
 
37.Fonseca R, Blood EA, Oken MM et al. Mytloma and the t(11;14)(q13;q32); 
evidence for a biologically defined unique subset of patients. Blood. 2002; 99: 
3735-41. 
 
38. Wilson CS, Butch AW, Lai R. et al. Cyclin D1 and E2F-1 immunoreactivity in 
bone marrow biopsy specimens of multiple myeloma: relationship to proliferative 
activity, cytogenetic abnormalities and DNA ploidy. British Journal of 
Hematology. 2001; 112: 776-82. 
 
39. Lessage DL, Troussard X, and Sola B. The enigmatic role of cyclin D1 in 
multiple myeloma. International Journal of Cancer. 2005; 115: 171-76.  
 
40. Ferres-Marco D, Gutierrez-Garcia I, Vallejo DM, Bolivar J, Gutierrez-Avino 
FJ, Dominguez M. Epigenetic silencers and Notch collaborate to promote 
malignant tumours by Rb silencing. Nature. 2006;439:430-436. 
 
41. Santarosa M, and Ashworth, A. Haploinsufficiency for tumor suppressor 
genes: when you don’t need to go all the way. Biochimica et Biophysica Acta. 
2004; 105-22. 278; 19358-66. 
 
42. Mohney BG, Robertson DM, Schomberg PJ, Hodge DO. Second nonocular 
tumors in survivors of heritable retinoblastoma and prior radiation therapy. Am J 
Ophthalmol. 1998;126:269-277. 
 
43. Gutierrez NC, Castellanos MV, Martin ML, et al. Prognostic and biological 
implications of genetic abnormalities in multiple myeloma undergoing autologous 
stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, 
whereas RB deletion as a unique abnormality is not associated with adverse 
prognosis. Leukemia. 2007; 21:143-150. 
 
44. Schmitt CA, McCurrach ME, de Stanchina E, Wallace-Brodeur RR, Lowe 
SW. INK4a/ARF mutations accelerate lymphomagenesis and promote 
chemoresistance by disabling p53. Genes Dev. 1999;13:2670-2677. 
 97 
45. Walkley CR, Shea JM, Sims NA et al. Rb Regulates Interactions between 
Hematopoeitic Stem Cells and their Bone Marrow Microenvironment. Cell. 2007; 
129: 1081-95. 
 
46. MacPherson D, Sage J, Kim T, et al. Cell type specific effects of Rb deletion 
in the murine retina. Genes and Development. 2004; 18: 1681-1694.   
 
47. Donovan SL, Schweers B, Martins R, et al. Compensation by tumor 
suppressor genes during retinal development in mice and humans. BMC Biology. 
2006; 4: 14. 
 
48. Viatour, P, Somervaille TC, Venkatasubrahmanyan S et al. Hematopoeitic 
stem cell quiescence is maintained by compound contributions of the 
retinoblastoma gene family. Cell Stem Cell. 2008; 3: 416-428. 
 
49. Sage, J., A. L. Miller, P. A. Pérez-Mancera, J. M. Wysocki, and T. Jacks. 
2003. Acute mutation of retinoblastoma gene function is sufficient for cell cycle 
re-entry. Nature 424:223-228. 
 
50. Casola S, Cattoretti G, Uytterspro N, et al. Tracking germinal center B cells 
expressing germ-line immunoglobulin -1 transcripts by conditional gene targeting. 
PNAS. 2006; 103: 7396-7401.  
 
51. Shackney, SE and Shankey TV. Cell cycle models for molecular biology and 
molecular oncology: exploring new dimensions. Cytometry. 1999; 35: 97-116. 
 
52. Chau BN, and Wang JY. Coordinated regulation of life and death by RB. 
Nature Reviews Cancer. 2003; 3: 130-38.  
 
53. Sharpless, NE and Depinho RA. Telomeres, stem cells, senescence and 
cancer. Journal of Clinical Investigation. 2004;113: 160-68.   
 
54.  Delston RB, and Harbour JW. Rb at the interface between cell cycle and 
apoptotic decisions. Current Molecular Medicine. 2006; 6: 713-18. 
 
55. Ma D, Zhou, P, Harbour JW. Distinct mechanisms for regulating the tumor 
suppressor and antiapoptotic functions of RB. The Journal of Biological 
Chemistry. 2003 
 
 
 
 
 
 98 
3.8 Figures and Tables 
 
 
 
 
 
Table 1 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 99 
 
 
 
 
 
 
Table 2 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 100 
 
 
Table 3 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 101 
 
Table 4 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 102 
 
Figure 1 
 
 
 
Figure 1. RB1 protein levels relate to genomic copy number in MM cell lines 
 
A. Western blot analysis of MM cell lines OPM2, RPMI 8226 (8226), KMS11, LP-
1, H929, UTMC2 and U266, using an antibody that detects RB1 independent of 
phosphorylation status (top, IF-8 antibody). HCT is colon cancer line used for a 
positive control.  Top band is RB1. Non-specific bands are marked by an 
asterisk. Duplicate blots were probed with a phospho specific RB1 (Serine 
807/811: P807/811) antibody (bottom). Actin was used as a loading control. B. 
Representitative FACS analysis of three MM cell lines analyzed for RB1 protein 
(Phospho RB Serine 807/811). U266 cells have no RB1 protein, LP1 cells have 
one copy and OPM2 has two.  
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Figure 2 
 
 
Figure 2. Hematopoeitic cell subsets in Rb1 WT and HET mice are similar 
A. Representative FACS analysis of spleen and bone marrow isolated from Rb1 
WT or HET mice using B cell (B220), T cell (CD4/CD8), and myeloid 
(MAC1/GR1) markers. Representative plots shown. Compiled FACS analysis of 
spleen (B.) and bone marrow (C). Black bars represent WT mice, and gray bars 
represent HET mice.  Error bars are standard deviation. n=4, WT; n=6, HET  
D. Spleen weights of WT or HET Rb1 mice seven days post treatment with PBS 
as a control or sheep red blood cells to induce germinal centers 
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Figure 3 
 
 
 
 
 
Figure 3. RB1 is expressed in myeloma, but rarely phosphorylated 
Shown is a representative patient sample (UPN 35945) that was stained with 
CD138 (left), total RB1 independent of phosphorylation status (4H1; middle) or 
phoshorylated RB1 (phospho Serine 807/811).  
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Table 5 
 
 
 
Table 5. Summary of RB1 IHC Analysis in primary patient myeloma samples                                        d   
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Chapter 4 
 
 
Characterization of Neurobeachin (NBEA,  
 
BCL8B) in myeloma and hematopoeisis 
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O’Neal, et al.  Neurobeachin (NBEA) is a target of recurrent interstitial deletions 
at 13q13 in patients with MGUS and multiple myeloma. Exp. Hem. 2009; 37:234-
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4.1 Abstract 
A role potential role for NBEA in myeloma was revealed by its identification at 
sites of interstitial deletions in DNA isolated from primary patient MGUS and MM 
samples (Chapter 2). We found NBEA was decreased in patient samples with 
monosomy 13 vs. those that retained both copies, but in some MM cell lines and 
patient samples, NBEA expression was high. RNAi mediated knockdown of 
NBEA in OPM2 cells that express high endogenous NBEA grew poorly 
compared to controls, suggesting these cells required NBEA for growth. Our 
expression analysis of Nbea in the hematopoietic system revealed it was 
expressed in spleen in thymus. Colony assays performed on Nbea-/- and Nbea+/+ 
fetal liver cells revealed no differences between genotypes, suggesting 
hematopoietic progenitor cells in Nbea-/- mice are functional. To determine if 
Nbea was required for adult hematopoeisis, we performed fetal liver transplants 
using Nbea+/+ and Nbea-/- donor cells and found Nbea was dispensable for 
engraftment and basal adult hematopoietic development.  
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4.2 Introduction 
4.2A Neurobeachin (NBEA, BCL8B) is a BEACH domain containing protein 
implicated in vesicle trafficking 
We identified interstitial deletions affecting NBEA, and found it to be the sole 
gene affected in a minimally deleted region at 13q13 in DNA isolated from 
patients with PC dyscrasias (Chapter 2). NBEA is large; it’s genomic sequence 
spans 0.73Mb and produces a 9.5Kb transcript encoding a 327KDa protein. 
NBEA has homologs in mice (Nbea), C elegans (Sel-2), which is shared with 
LRBA [1], and drosophilia  (rugose, DAKAP550). NBEA protein is comprised of a 
BEACH, Pleckstrin Homology (PH), WD40 and a Protein Kinase A (PKA) binding 
domains (Figure 1). 
 
The BEACH domain was first discovered in the protein encoded by the 
Lysosomal Trafficking Regulator gene (LYST, CHS1). Homozygous deletions 
within the CHS coding sequences resulting in expression of truncated proteins 
missing the BEACH domain are found in patients with Chediak-Higashi 
Syndrome (CHS) [2-4]. This is a rare, autosomal recessive disorder 
characterized by variable albinism, bleeding tendency, progressive neurologic 
abnormalities and severe immunodeficiency with lack of natural killer cell activity. 
The cellular hallmark of CHS is enlarged lysosomal and lysosomal related 
organelles in almost all granulated cells [5-7], suggesting the BEACH domain 
regulates vesicle size, structure or function [5,7].  
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Other mammalian BEACH encoding proteins are implicated in aspects of vesicle 
function [5]. LPS-Responsive Vesicle Trafficking, Beach and Anchor containing 
(LRBA, BGL, CDC4L), which like NBEA, encodes a Protein kinase A (PKA) 
binding domain (discussed in section 4.2), is implicated in vesicle release in 
polarized cells [8]. Neutral Spingomyelinase Activation Associated Factor 
(NSMAF, FAN) encoding the protein FAN is implicated in TNF signaling and 
activation of neutral sphingomyelinase. Nsmaf deficient mice have slightly 
enlarged lysosomes [9]. The protein encoded by the WD Repeat and FVYE 
Domain-containing 3 (WDFY3, ALFY) gene binds Phosphoinositol 3 phosphate 
that regulates endocytic and autophagic trafficking [5]. Finally, NBEA is 
implicated in induced vesicular release at the neuromuscular junction [10, 11].  
 
Crystal structure analysis of the BEACH domain and the 130 amino acids N-
terminal to it revealed it is situated C-terminal to a structurally conserved PH 
domain [12]. These two domains physically interact, suggesting they function as 
a single unit [12]. Although PH domains can bind either to fatty acids or proteins, 
the interaction of the PH domain with the BEACH domain physically blocks the 
alpha helix known to mediate fatty acid binding, suggesting the PH domain of 
NBEA mediates protein-protein interactions [12]. 
 
4.2B NBEA is a Protein Kinase A (PKA) Anchoring Protein (AKAP) 
The NBEA gene encodes a transcript generating a protein that includes a PKA 
binding site. The term PKA comprises its enzyme complex composed of four 
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regulatory subunits (RIα,  RIβ ,RIIα and RIIβ) and two catalytic subunits (Cα and 
Cβ) with serine/threonine kinase activity that is activated in response to increases 
in cAMP.  Murine Nbea binds to PKA regulatory subunits RIIα (Kd: 10nM) and 
RIIβ  (Kd: 30nM) [10] and since murine and human PKA regions are highly 
conserved, human NBEA is predicted to bind PKA. Neurobeachin is therefore 
characterized as an AKAP that localizes PKA to correct cellular locations such 
that upon cAMP increases, PKA signaling only occurs at correct locations, 
facilitating appropriate phosphorylation of downstream targets.  
 
4.2C NBEA expression is highest in brain 
NBEA transcripts and protein are detected at very high levels in both mouse and 
human brain [10-13; our own data). Lower, but relatively robust transcripts are 
found in the uterus, adrenal gland, ovary, testes, lung, and kidney with even 
lower expression in heart, spleen, stomach, and small intestine  [11,13]. Mice 
that lack Nbea die immediately after birth due to a block in synaptic transmission 
at the neuromuscular junction, supporting a functional role in the nervous system 
[11]. 
 
A potential role for NBEA in myeloma was revealed by its identification at sites of 
interstitial deletions in DNA isolated from primary patient MGUS and MM 
samples (Chapter 2). A prior study showed increased NBEA expression with 
advancing disease stage in primary plasma cell dyscrasias [14], and in another 
study was one of a small set of genes whose expression was increased in patient 
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samples harboring single chromosome 13 deletions [15]. We found NBEA was 
decreased in patient samples with monosomy 13 vs. those that retained both 
copies, but in some MM cell lines and patient samples, NBEA expression was 
high. RNAi mediated knockdown of NBEA in OPM2 cells (that express high 
endogenous NBEA) grew poorly compared to controls, suggesting these cells 
require NBEA for growth. Our characterization of Nbea expression in the 
hematopoietic system revealed it was expressed in spleen in thymus. Colony 
assays performed on Nbea-/- and Nbea+/+ fetal liver cells revealed no differences 
between genotypes, suggesting hematopoietic progenitor cells in Nbea-/- mice 
are functional. To determine if Nbea was required for adult hematopoeisis, we 
performed fetal liver transplants using Nbea+/+ and Nbea-/- donor cells that 
revealed Nbea was dispensable for engraftment and basal adult hematopoietic 
development.  
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4.3 Methods 
4.3A Microarray Expression Analysis 
Two independent microarray datasets were analyzed. First, a Mayo Clinic 
dataset [16] included 162 samples (101 MM, 24 SMM, 22 MGUS, and 15 normal 
PC’s; GEO GSE6477; chromosome 13 status was determined by FISH). Second, 
we used a multiple myeloma research consortium (http://www.themmrc.org; 
MMRC) dataset that included 100 MM samples (Chromosome 13 status was 
determined by aCGH).  
 
Expression values were derived against a PM/MM difference background using 
Robust Multichip Average (RMA) [17]. Present/Absent probes were called using 
Affymetrix Microarray Suite version 5. Only probes detected in at least one 
sample were used in subsequent comparisons. In pooled Chromosome 13 
Deletion versus no Deletion comparisons, Significance Analysis of Microarrays 
(SAM), [18] was used to detect differentially expressed genes based on a q-value 
of less than 5%. SAM was run with 100 permutations for correction of False 
Discovery Rate. These genes were clustered and visualized in DChip [19] 
(http://www.dchip.org). aCGH data was first smoothed with region=2, outlier scale 
=4, smoothing SD=2 and trimming proportion of 0.025. CBS was then run with 
default parameters (alpha=0.01, window.size= NULL, with 10000 permutations). 
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4.3B Q-RT-PCR 
RNA was isolated from whole tissues harvested from 4 week-old C57BL/6 mice 
using Trizol Reagent (Roche Molecular Biochemicals, Indianapolis, IN) per 
manufacturer’s instructions.  First strand cDNA was generated using SuperScript 
First Strand Synthesis Kit (Invitrogen, Carlsbad, CA) per manufacturer’s 
directions. Prior to lysis in trizol reagent, red blood cells were removed from bone 
marrow by brief incubation in hypotonic lysis buffer (150 mM NH4Cl, 10 mM 
KHCO3, 0.1 mM EDTA, pH 7.4). Standard curves were made using cDNA 
generated from brain RNA (input range: 25ng to 0.3ng). Standard curve graphs 
were generated by plotting the cycle threshold (Ct) versus the log of DNA input 
concentration and reactions analysed using the standard curve method 
(www.appliedbiosystems.com). Assays were performed with Taqman Universal 
PCR Master Mix with the total volume of each reaction 25µl.  Primer 
concentration: 900nM; probe concentration: 2.5mM, 12.5ng template. 
Experimental reactions were run in triplicate and presented as the average of two 
separate experiments. Error bars are standard deviation of duplicate runs. 
Reactions were run on 7300 Real Time PCR System, and analyzed using 7300 
System Software (Applied Biosystems, Foster City, CA). Primers: Nbea Exon6F: 
A5’GG TTT CCA GCA CTG TGT GAA GT3’ Nbea Exon7R: 5’TGT GGA CGA 
TGC TGA TCA TGT3’ Nbea Probe 5’6-FAMTGA TTT CCA GCC TCG CAA 
GTG36TAM3’ GapdhF 5’TGC ACC ACC AAC TGC TTA G3’ GapdhR 5’GGA 
TGC AGG GAT GAT GTT3’ Gapdh Probe5’6FAMCAG AAG ACT GTG GAT 
GGC CCC TC36TAM3’. 
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4.3C Western Blot Analysis 
Tissues for generation of cell lysates were harvested from 5-6 week old C57BL/6 
mice. Lysates were isolated from mouse whole tissues by cutting tissues with 
scissors in tissue lysis buffer (0.32M sucrose, 1mM EDTA, 10mM Tris pH 7.6, 
with inhibitors as described [20] and cells homogenized for 20 seconds. Samples 
were placed on ice for ten minutes, and spun to pellet unlysed cellular debris. 
Lysates were run on gels with three layers: 4% stack, 5%resolving and 9% 
resolving gels. The NBEA polyclonal antibody was generously provided by 
Manfred Kilimann (Department of Cell and Molecular Biology, Uppsala 
University, Sweden). 
 
4.3D Lentiviral infection and knockdown of NBEA 
Lentiviral vectors encoding siRNA targets to NBEA and controls were purchased 
from Sigma (St. Louis, MO). Si1: CGGGATGAAATTCGCAGTGTT  Exon 2; Si2: 
CCGACTCTTTGCAGTGAATA Exon 51; Si3: GGACTACAATGTTTCGTCGTATT 
Exon 24. Lentivirus was generated using calcium phosphate mediated 
transfection of 293T cells using the purchased expression vectors and packaging 
sequences. Viral supernatents were used to infect OPM2 or LP1 cells for 
1.5hours and 2500rpm. One day after infection, cells were plated in (0.5µg/ml) 
puromycin and after 1 week (when all mock infected cells treated with puromycin 
were dead), 100,000 cells were plated in triplicate and counted using trypan blue 
exclusion daily (samples were blinded to person counting).  
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4.3F Fetal liver transplants and colony assays 
Nbea+/+ (WT), Nbea+/- (HET) and Nbea-/- (KO) or fetal livers were obtained from 
day 13.5-15.5 d.p.c. fetuses. These were generated by timed matings of Nbea 
heterozygous mice (breeder pairs were allowed to breed for three nights, and 
then male was removed). Fetuses were placed in PBS, and fetal livers isolated 
by dissection. Fetal livers were placed in 1ml Fetal Liver Transplant Media 
(FLTM; RPMI containing 1% pen/strep, 20% fetal bovine serum, 10 ng/mL IL6, 
100 ng/mL SCF, 50 ng/mL FLT3, and 10 ng/mL Tpo), passed through a 27.5 
gauge needle attached to a 1 ml syringe to break up cell clumps and red blood 
cells lysed using hypotonic lysis buffer (150 mM NH4Cl, 10 mM KHCO3, 0.1 mM 
EDTA, pH 7.4).  Cells were incubated for 48 hours at 37oC at 5% CO2 in FLTM 
and 1.5-2 X 10^6 cells were injected by lateral tail-vein into lethally irradiated 
(1100 or 1200 rads) Ly5.1 mice (to facilitate evaluation donor chimerism).  On the 
day of transplant, 5X10^5 (M3630) or 2X10^4 (M3434) were plated in triplicate 
into methocellulose (Stem Cell Technologies, Vancouver, Canada) and counted 
on day seven.  
 
4.3E Flow Cytometric analysis 
Spleen, bone marrow and blood were harvested from recipient mice 8-10.5 
weeks post transplant. Single cell suspensions of spleen cells were made by 
passing cut-up spleens through 100µm cell strainer (BD Falcon, Bedford, MA) 
and spun at 1500 rpm. RBC’s were lysed as above.  Single cell suspensions 
were stained with B220, CD43, DX1, TER119, MAC1, GR1, CD23, IgM, CD4, 
and CD8 (ebiosciences, San Diego, CA) for 30 minutes on ice. Data were 
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collected using Cytomics FC 500 (Beckman Coulter, Fullerton, CA). Figures were 
prepared using FloJo software (Tree Star, San Carlos, CA). 
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4.4 Results 
 
4.4A NBEA expression in MM samples with monosomy 13 
 
We identified interstitial deletions affecting NBEA, and found it to be the sole 
gene affected in a minimally deleted region at 13q13 in DNA isolated from 
patients with PC dyscrasias (Chapter 2). NBEA has no known role in myeloma, 
although transcripts assessed by expression microarrays were associated with 
disease progression in myeloma [14]. We sought to validate NBEA as a deletion 
target by characterizing its expression in MM cells. We anticipated that patient 
samples harboring monosomy 13 would have lower NBEA expression than 
patient samples without chromosome 13 deletions.  We analyzed two large 
microarray data sets (methods; total n=262) for expression changes based on 
chromosome 13 status.  In both datasets, NBEA transcript levels were 
significantly decreased in patient samples with monosomy 13 versus those 
without, revealing NBEA expression levels were related to genomic copy number 
(Table 1).  
 
 
We developed a quantitative real-time reverse transcriptase PCR (Q-RT-PCR) 
assay to quantitate NBEA transcript expression, and first assayed a panel of MM 
cell lines.  Some myeloma cell lines expressed low levels of NBEA transcript, as 
anticipated, but surprisingly, several expressed NBEA at high levels (Figure 2). 
We found UTMC2 cells expressed NBEA at levels three times higher than in a 
human brain sample, where NBEA is normally most highly expressed [10-13, our 
own data]. OPM2 cells had levels 30% of brain while U266 had levels 18% of 
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brain. RPMI-8226 and LP1 had low/undetectable NBEA transcripts (Figure 2). 
We next examined NBEA protein levels in these cell lines by Western Blotting of 
whole cell lysates. Consistent with the Q-RT-PCR data, we found NBEA protein 
expression varied significantly between cell lines (Figure 2). The UTMC2, OPM2, 
and H929 cell lines had the highest NBEA protein levels, while RPMI 8226, U266 
and LP1 had low to undetectable NBEA protein.  
Finally, we measured NBEA transcripts and protein levels in a set of CD138-
enriched primary MM bone marrow samples (n=14) using Q-RT-PCR and 
Western blotting. We found NBEA transcript expression varied significantly 
across samples and, consistent with our MM cell line data, some MM patient 
samples, even with monosomy 13, harbored high NBEA transcript levels (Figure 
2). Because of the large number of CD138 cells needed for Western analysis we 
were forced to analyze a separate set of MM patient samples by Western blot 
(only sample 14216 had both RNA and protein data; expression was low by both 
analyses). Consistent with the RNA data, Western blotting using an NBEA-
specific antibody demonstrated that NBEA protein was strikingly dysregulated in 
patient MM cells (Figure 2).  
4.4B Decreased NBEA expression caused a reduction in OPM2 cell growth  
Our initial NBEA expression data revealed it was robustly expressed in a subset 
of MM cell lines including OPM2, UTMC2, and H929. We hypothesized high 
levels of NBEA would be required for MM cell growth.  To address this 
hypothesis, we used SiRNA-mediated knockdown of NBEA in OPM2 cells. 
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OPM2 cells were infected with a lentivirus expressing a double- stranded small 
interfering RNA (siRNA) directed to NBEA, or vector alone. Efficient knockdown 
of NBEA protein with three separate NBEA silencing target sequences (siRNA1, 
siRNA2, and siRNA3) was demonstrated (range: 11-72% of vector; Figure 3). 
After infection and selection in puromycin, 100,000 cells from each construct 
were plated in triplicate and live cells were counted by trypan blue exclusion for 
five days. Compared to empty vector control (Figure 3), and a vector expressing 
a non-targeting siRNA (not shown), OPM2 cells infected with lentivirus 
expressing siRNA targeted to NBEA revealed a dramatic decrease in growth rate 
that was most pronounced with siRNA2, which caused the most efficient 
reduction in NBEA protein (Figure 3).  
 
To confirm this result was specific to cells expressing high levels of NBEA, the 
experiment was repeated in LP1 cells that express low levels of NBEA protein 
(Figure 2). We found that although the cells infected with NBEA siRNA displayed 
reduced growth compared to vector control (67% or 63% of control cells for Si1 
and Si2, respectively on day 5 of culture), these cells grew much better than the 
OPM2 cells (51% or 20% for Si1 and Si2, respectively on day 5 of culture, Figure 
3). The slightly reduced growth indicates either a low level of siRNA toxicicity in 
LP1 cells, or that reduction of even the low levels of NBEA was enough to 
generate a slight growth disadvantage. Infection of LP1 cell lines with siRNAs 
targeting RB1 (not shown) did not result in a growth disadvantage, suggesting 
the reduced growth is not the result of siRNA toxicity.  Although the mechanism 
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of altered growth in OPM2 cells is not currently fully understood, these data 
suggest expression of NBEA is required for normal growth of OPM2 cells and 
that expression of NBEA may play a role in tumor maintenance, or that NBEA 
provides a required survival signal.  
 
 
4.4C Nbea is expressed in spleen and thymus 
Because NBEA is dysregulated in plasma cell dyscrasias, we sought to 
determine its expression levels in hematopoietic tissues. Qualitative analysis has 
been performed on a tissue panel including spleen [11,13], but other 
hematopoietic cell types including bone marrow and thymus have not been 
examined. To quantitatively assess Nbea transcript levels, we performed  
Quantitative Real-Time PCR (Q-RT-PCR) on cDNA isolated from a panel of 
murine tissues including heart, lung, kidney, liver, and the hematopoietic tissues 
bone marrow, spleen and thymus (Figure 4). Consistent with prior reports 
[11,13], Nbea transcript levels were higher in lung, kidney and heart tissues than 
liver, validating our Q-RT-PCR system. We found spleen and thymus had higher 
Nbea transcript levels (Nbea:Gapdh ratio: 0.1 and 0.055, respectively) compared 
to liver (Nbea:Gapdh ratio: 0.03) and Nbea was almost undetectable in bone 
marrow (Nbea:Gapdh ratio: 0.0009).  
 
To determine if Nbea protein levels in murine tissues were related to transcript 
levels, Western Blot analysis was performed on whole tissue lysates isolated 
from kidney, liver, thymus and spleen. We found Nbea protein in kidney, thymus, 
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and spleen but very low protein in liver, consistent with the Q-RT-PCR analysis 
(Figure 4). No Nbea protein was detected in Nbea-/- fetal brain tissue but robust 
detection of Nbea was found in adult and fetal brain lysates isolated from control 
mice, as expected.  
 
4.4D Nbea is not required for myeloid or pre-B cell colony formation 
Because we identified NBEA as a target in the B cell cancer myeloma and also 
showed it was expressed in hematopoietic tissues, we hypothesized its 
expression would be required for hematopoietic development. Since Nbea-/- mice 
die at birth [11], we performed timed breedings to isolate day 14.5-15.5 d.p.c. 
fetal liver cells since that is time of maximal hematopoietic stem cell activity in 
developing embryos [21,22]. Nbea+/+, Nbea+/- and Nbea-/- fetal liver cells were 
plated in directly into methocellulose cultures containing either myeloid or pre-B 
cell cytokines (Figure 5, methods). We found Nbea-/- and Nbea+/- fetal liver cells 
were as proficient as Nbea+/+ fetal liver cells in their ability to form colonies of 
both myeloid and pre B cell type, suggesting hematopoietic progenitor cells in 
Nbea-/- mice are functional. 
 
4.4E Nbea is dispensable for engraftment and basal adult hematopoeitic 
development  
To determine the requirement of Nbea to in vivo baseline hematopoietic 
engraftment and development, we performed fetal liver transplantation assays. 
Fetal liver cells isolated from Nbea+/+ or Nbea-/- cells (Ly5.2/CD45.2) were 
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injected into lethally irradiated (Ly5.1/CD45.1) recipients and mice were analyzed 
8.5-10.5 weeks post transplant. PCR performed on DNA isolated from fetal liver 
cells and embryonic tissue, and Western blot analysis performed on fetal brain 
tissue confirmed appropriate genotypes (Figure 5). The Ly5.2/Ly5.1 (common 
leukocyte antigens) were used to quantitate donor chimerism. We found on 
average (92%, 86%, 90%) percent donor (Ly5.2) cells in blood, spleen and bone 
marrow, respectively, demonstrating successful engraftment (Figure 6, data not 
shown).  
 
Peripheral white blood counts were similar in recipient mice injected with either 
Nbea+/+ or Nbea-/- donor cells (WT mean: 8.25k/µl, range 5.38-10.58; KO mean: 
5.9k/µl, range 3.86-7.24, n=4 both groups), as were spleen weights (WT mean: 
0.029g, range 0.027-0.03; KO mean: 0.033g, range 0.028-0.043, n=4 both 
groups). To examine whether there were differences in cell type distribution, 
FACS analysis was performed in bone marrow and spleen. In bone marrow, we 
found similar numbers of myeloid (GR1/Mac1), T cells (CD4, CD8), B cells 
(B220), NK cells (DX5) and erythroid (Ter119) cells in both WT and KO chimeras 
(Figure 6).    In spleen, we also found similar numbers of all cellular subtypes 
listed above, although in one outlier mouse, we saw increased Ter119 in an 
Nbea-/- reconstituted chimera (not shown).    
 
We examined further the B cell compartment since NBEA expression is 
dysregulated in PC dyscrasias. To this end, spleen cells were stained with IgM, 
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CD23 and CD43. IgM marks splenic B cells, which can be further divided into 
Follicilar (IgM+CD23+), Marginal Zone and Immature B cells (IgM+CD23-CD43-), 
and B-1 cells (IgM+CD23-CD43+). We found similar numbers of these B cell 
subsets in recipient mice of both genotypes, suggesting Nbea was dispensable 
for basal B cell development (Figure 6).  Together, although NBEA is 
dysregulated in MM, and expressed in hematopoietic tissues, Nbea was 
dispensable for engraftment and basal adult hematopoietic development 
including formation of mature B, T, NK, and myeloid cells when assayed in 
steady-state conditions. Future experiments are required to assess the functional 
capabilities of these cells in stress conditions.  
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4.5 Discussion 
 
The reduced expression of NBEA in samples harboring monosomy 13 
suggests NBEA is a novel tumor suppressor gene.  
A functional role for NBEA in MM was suggested by the dysregulation of its 
expression in MM patient samples. DNA microarray data from a large number of 
patient samples (n=262) demonstrated that compared to patients with normal 
chromosome 13, there was a decrease in NBEA expression in patient samples 
harboring single copy loss of NBEA. These data suggest that NBEA may be a 
novel tumor suppressor gene in MM.   
 
To our surprise, our Q-RT-PCR and Western blot analysis performed on a 
separate cohort of MM samples revealed that some patients, even with 
monosomy 13, harbored very high NBEA expression, suggesting instead a pro-
tumor role for NBEA in MM (Figure 3). However, inactivating mutations in the 
p53 tumor suppressor gene are often associated with high p53 expression [23], 
so these data may still be consistent with a role for NBEA as a tumor suppressor. 
Sequencing of NBEA genes in MM patient samples will be required to prove that 
NBEA mutations occur in myeloma that potentially result in expression of 
functionally null NBEA protein.  
 
Mice heterozygous for tumor suppressor genes are often tumor prone. For 
example, Rb1 heterozygous mice develop pituitary tumors that have undergone 
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mutation at the remaining allele [24]. We are currently aging a cohort of Nbea+/- 
and Nbea+/+ mice (n=15 for each genotype) to determine if the Nbea+/- mice 
succumb to tumors. The oldest mice are 587 days old and appear healthy, 
arguing against a tumor- suppressor function for Nbea. Mating Nbea 
heterozygous mice to tumor prone strains can be used to determine if decreased 
Nbea reduces time to disease onset or increases disease severity compared to 
wild type controls. Eµ-XBP-1 mice develop MGUS and progress to MM with lytic 
bone lesions [25]. If Nbea functions as a tumor suppressor, Eµ-XBP1 mice mated 
to Nbea+/- mice are predicted to succumb to disease with decreased latency or 
increased severity.  
 
Since Nbea null mice die at birth [11], generation of mice with conditional deletion 
of Nbea in plasma cells is required to determine the effects of plasma cell 
specific deletions of Nbea.  This can be accomplished by generating NbeaFlox/Flox 
mice, and then breeding them to the Cγ1-CRE mice, which express CRE in post 
germinal center plasma cells upon antigen stimulation [26]. Analysis of Cγ1-CRE 
NbeaFlox/Flox and Cγ1-CRE Nbea+/+ plasma cells will determine whether deletion of 
Nbea specifically in plasma cells alters that compartment.  
 
Robust detection of NBEA in MM suggests an oncogenic function 
On the other hand, the high-level NBEA expression detected in a subset of MM 
primary samples and cell lines supports the hypothesis that NBEA, when 
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expressed, plays a pro-tumor role in PC dyscrasias. A prior study showed 
increased NBEA expression with advanced disease stage in primary plasma cell 
dyscrasias [14].  Furthermore, NBEA was one of a small set of genes whose 
expression was increased in monosomy 13 patient samples in another study 
[15].  Nbea was upregulated almost seven fold in mature versus less mature B 
cell tumors in two separate mouse models [27]. In our microarray study, although 
most patient samples with deletion 13 revealed decreased NBEA levels, there 
were identifiable outliers with robust expression of NBEA (Figure 2, not shown). 
Additionally, Q-RT-PCR and Western Blot analysis on a subset of patient 
samples expressed high levels of NBEA, and a number of those patient samples 
had poor prognosis, suggesting a potential association. Large-scale analysis of 
NBEA (via Q-RT-PCR or Western blotting) is needed in uniform patient groups 
(i.e. with similar treatment regimens) to address the hypothesis that elevated 
expression of NBEA relates to poor patient outcome.  
 
Examining functional properties of genes related to NBEA can shed insight to the 
hypothesis that NBEA functions as an oncogene. NBEA shares 62% sequence 
identity at the amino acid level to LRBA, a homolog encoding both a BEACH and 
PKA domain, and is implicated in cancer cell growth [28]. Knock-down of LRBA 
in cancer cell lines decreased the growth of cells in culture, and was found to be 
upregulated by E2F and downregulated by P53. These authors proposed that 
LRBA functions as an oncogene by facilitating EGFR [28].  Knockdown of NBEA 
in OPM2 cells led to reduced growth (Figure 3). We have undertaken the task of 
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subcloning the entire NBEA cDNA for use in overexpression studies. We initially 
planned on using a retroviral mediated high level expression and bone marrow 
transplantation system to express NBEA in mouse hematopoietic cells, but have 
been unable to accomplish this, since the large size of NBEA has prevented 
generation of high-titer retrovirus. We are currently generating a DNA construct 
to direct expression of NBEA to B cells using the Eµ regulatory sequences in a 
transgenic mouse model.   
 
The requirement of NBEA for OPM2 growth suggests a survival function.  
Our data that OPM2 cells grew poorly when NBEA levels were decreased, 
suggests NBEA provides a survival signal. The interpretation of this data is 
confounded by the fact that until sequenced, we do not know if wild type or 
mutated NBEA protein is expressed in OPM2 cells (and in samples isolated from 
patient with PC dyscrasias). However, the conclusion remains the same: cells 
that express NBEA required its expression for growth. It is an unanswered 
question as to what cellular function NBEA is providing to these cells (discussed 
further in Chapter 5). 
 
Nbea is dispensable for adult hematopoietic engraftment and development 
in fetal liver transplant system 
We showed Nbea was expressed in spleen and thymus tissues in steady state 
conditions. IHC staining for Nbea in spleen sections will determine the spleen 
localization of Nbea. Also, experiments are underway to sort spleen cell subsets 
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based on cell surface expression of cell type specific markers (GR-1, B220, CD4, 
CD8, DX5) followed by Q-RT-PCR. Because Nbea is dysregulated in myeloma, 
we hypothesize Nbea is expressed in plasma cells. To determine if Nbea is 
expressed in plasma cells, mice will be challenged with sheep red blood cells 
and plasma cells will be sorted using cell surface markers PNA/B220 one week 
post injection when formation of spleen GCs are maximal [29]. Q-RT-PCR will be 
used to quantitively assess Nbea expression in these cells.  
 
We showed Nbea was dispensable for engraftment and basal adult 
hematopoietic development including formation of mature B, T, NK, and myeloid 
cells when assayed in steady-state conditions (Figure 5,6). This was somewhat 
surprising based on the finding Nbea was expressed in spleen (Figure 4). 
However, we did not examine plasma cell development or function in our fetal 
liver transplantation assay. Therefore, it remains a possibility Nbea has a function 
in plasma cells (perhaps by promoting plasma cell differentiation or production of 
class switched antibodies).  
 
To test the hypothesis Nbea-/- plasma cells have defects in germinal center 
formation, Nbea KO and Nbea WT chimera reconstituted mice will be challenged 
with SRBC, and flow cytometry for detection of germinal center plasma cells 
(PNA+/B220+) will be performed [29]. If NBEA functions in vesicle traffic or PKA 
mediated regulation of AID in class switch recombination (CSR) or secretion, 
Nbea null plasma cells may have deficiencies in antibody formation and/or 
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secretion. To assess this, we will use our fetal liver transplantation system to 
generate mice with null or wild type Nbea hematopoietic systems. In vivo 
analysis of basal CSR will be assessed by performing ELISA assays on serum 
and levels of IgM, IgG1, IgG2a, IgG2B, IgG3 and IgA will be determined [30]. If 
Nbea null chimeras are deficient in CSR, it predicts detection of IgM (which does 
not undergo CSR), but not the other isotypes. If there are secretion defects, 
detection of all antibody isotypes is predicted to be low/undetectable.  
 
To assess CSR in an antigen stimulated system, mice will be injected with SRBC 
and serum will be subject to ELISA for IgM and IgG1 over a three-week time 
course. In vitro assessment of class switch recombination will be performed by 
isolating splenocytes from engrafted mice (Nbea+/+ and Nbea-/-) by stimulating 
purified B cell splenocytes with LPS, LPS and Il-4, pr LPS and TGFβ and then 
quantitating antibody isotypes in culture supernatents by ELISA as described 
above [27, 30, 31].  
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Figure 1 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. NBEA protein and exon structure 
A. NBEA protein domains. Numbers correspond to amino acids. B. 
NBEA exon structure. Some exons are numbered (top) and sizes of 
the four largest introns are shown on bottom.  
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Table 1 
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Figure 2 
 
 
Figure 2. NBEA is variably expressed in myeloma 
A. Quantitative Q-RT-PCR analysis of NBEA on a panel of MM cell lines. NBEA 
levels were normalized to GAPDH and plotted as a percentage of human brain 
where NBEA expression is known to be high.  B. Western Blot analysis of NBEA 
on a panel of human MM cell lines. Murine brain (mBrain) was used as positive 
control and HSP90b is shown as loading control.  C. Quantitative RT-PCR 
analysis of NBEA on a panel CD138 purified primary patient samples including 
nine of the 20 patient samples included in aCGH analysis plus an additional five. 
White bars indicate patient samples with normal chromosome 13 status. Gray 
bars indicate patient samples with full or partial chromosome 13 deletions 
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(determined by cytogenetics, FISH or aCGH analysis). NBEA levels were 
normalized to GAPDH and plotted as a percentage of human brain as in A. D. 
Western Blot analysis on CD138 purified lysates from five primary patient 
samples. Due to limited sample quantity, these patients are different from the 
twenty included in aCGH analysis. HSP90b was used as loading control. KMS11 
is MM cell line shown since repeat analysis showed NBEA protein levels were 
low.   
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Figure 3 
 
 
Figure 3. NBEA is required for growth of OPM2 cells 
 
A. Western Blot analysis of OPM2 cells infected with lentivirus expressing 
nothing, or one of three siRNAs that target NBEA.  Uninfected OPM2 cells are 
shown as a control. HSP 90 was used as loading control and for controls in 
densitometry results, shown below blot. B. Growth curves of OPM2 or LP1 cells 
infected with vector alone or siRNA targeting NBEA. Cells were selected in 
puromycin for one week and then 100,000 cells from each group were plated in 
triplicate and live cells counted using trypan cell exclusion. Error bars are 
standard deviation of a representative triplicate experiment.  
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Figure 4  
 
 
 
Figure 4. Nbea is expressed in thymus and spleen 
A. Q-RT-PCR analysis of Nbea was performed on a panel of murine tissues. 
Data are plotted as the ratio of Nbea/Gapdh signal. Reactions were performed in 
triplicate and experiment was performed in duplicate. Error bars are standard 
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deviation of two separate experiments.  B. Western blot analysis of Nbea in 
panel of whole tissue lysates. 
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Figure 5 
 
 
 
 
Figure 5. Nbea is not required for myeloid or Pre-B cell colony formation 
A. Western Blot analysis of lysates isolated from fetal brains. Brains from each 
fetus are numbered. N; negative control lysates from a separate fetal liver brain 
known to be null for Nbea. B. Cells were plated into M3630 that supports pre B 
cells. WT, HET or KO fetal liver cells were plated in methocellulose in triplicate. 
WT (n=1), HET (n=2), KO (n=3). Data from same genotypes were pooled. Error 
bars are standard deviation of averages of each well scored. C. WT, HET or KO 
fetal liver cells were plated in methocellulose containing myeloid (M3434) 
cytokines. Absolute colony numbers of G, M, MG or E colonies are plotted. WT 
(n=1), HET (n=2), KO (n=3). Cells were plated in triplicate. Data from same 
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genotypes were pooled. Error bars are standard deviation of averages of each 
well scored. D. Percentage of total colonies counted in C. 
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Figure 6 
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Figure 6. Nbea is dispensable for broad reconstitution of major 
hematopoietic lineages following transplantation 
A. FACS analysis of spleen (left) and bone marrow (right) of recipient mice 
transplanted with either Nbea+/+ or Nbea-/- fetal liver donor cells. B and C. 
Summary of Spleen FACS analysis shown in A. of wild type (black bars) and 
knockout (white bars) recipient mice. Data are presented as mean of four mice 
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per group. Error bars are standard deviation. MZ/I: Presented as percentage of 
IgM+ cells that were CD23-CD43-. Follicular: Presented as percentage of IgM+ 
cells that were CD23+. B-1 cells: Presented as percentage of IgM+ cells that 
were CD23-, CD43+. MZ: marginal zone; I: immature; FL: Follicular, NK: natural 
killer.  
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Summary and Future Directions 
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5.1 Summary  
Numeric or structural chromosomal abnormalities are detected in nearly all 
patients with plasma cell dyscrasias, including primary amyloidosis, monoclonal 
gammopathy of undetermined significance (MGUS) and multiple myeloma (MM) 
[1]. Chromosome 13 deletions, most frequently monosomy 13, are detected in 
10-20% of MM cases by routine cytogenetics or metaphase fluorescent in situ 
hybridization (FISH) and are a significant predictor of shortened survival [2-4]. 
Previous efforts to map somatically acquired chromosome 13 localized DNA 
copy number losses have been hampered by their relatively low-resolution 
approaches [5-14]. The goal of this thesis was to identify chromosome 13 genes 
affected by copy number loss in primary patient samples isolated from patients 
with plasma cell dyscrasias. Our analysis (using unprecedented high-resolution 
techniques and appropriate controls), identified two distinct minimally deleted 
regions on chromosome 13, each defined by deletions affecting one gene: NBEA 
at 13q13 and RB1 at 13q14.2.  
 
5.2 Hypothesis 1: Rb1 haploinsufficiency contributes to myelomagenesis  
Our aCGH, cytogenetic, and FISH analysis of chromosome 13 in primary patient 
samples revealed that one copy of RB1 is a target of deletions in MM, yet in most 
patient samples (7/8 in our set) the other copy is retained in MGUS and MM 
(Chapter 2). No exonic RB1 mutations were detected in our sequence analysis 
performed on DNA isolated from CD138 purified plasma cells from 41 MM or 
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MGUS primary patient samples, suggesting RB1 alleles in MGUS and myeloma 
are wild-type (Chapter 3). We, and others [4,12,13] showed transcripts 
expressed from retained RB1 alleles are expressed at reduced levels in patient 
samples harboring monosomy 13 versus samples with two RB1 alleles (Chapter 
3). This suggests in myeloma and MGUS cells, retained RB1 alleles express 
transcripts that produce wild type RB1 protein. To address the hypothesis RB1 
protein would be inactivated by hyper-phosphorylation, we performed 
immunohistochemistry (IHC) analysis on paraffin-embedded bone marrow 
biopsies isolated from 25 patients with MGUS (1), SMM (1) MM (22) or PCL (1). 
We found hyper-phosphorylation of RB1 protein was a rare event in all samples 
tested. Together, these data suggest unmutated, hypo-phosphorylated RB1 
protein is expressed at reduced levels in MGUS and MM patient samples 
harboring monosomy 13.  Since deletions affecting RB1 are detected early in 
myelomagenesis, when rapid cell cycle does not occur, this suggests the 
contribution of reduced RB1 protein dose in myeloma is not via conventional 
uncontrolled proliferation found in other tumor types [15].   We hypothesize 
haploinsuffiency of RB1 contributes to myelomagenesis.  
 
Analysis of 8-9 week old Rb1+/+ versus Rb1+/- mice (backcrossed to generation 
10 C57BL/6) revealed no significant differences in steady state hematopoeisis or 
plasma cell induction after stimulation with sheep red blood cells (SRBCs; 
Chapter 3).  However, in Rb1 null retina cells, the Rb1 family member, p107 
compensates for Rb1 [16]. In hematopoeisis, p107 sometimes, [17] but not 
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always, [18] compensates for loss of Rb1. To avoid the issue of p107 
compensation completely, Rb1+/- mice are currently being bred to p107-/- mice to 
generate Rb1+/+p107-/- and Rb1+/-p107-/- mice. To determine whether 
haploinsufficiency of Rb1 is sufficient to alter the plasma cell compartment, 
serum will be analyzed every three months for detection of monoclonal protein by 
performing serum electrophoresis and immunofixation analysis. Total levels of 
serum protein will be assessed using serum protein electrophoresis (SPEP) 
analysis. We will assess for detection of increased plasma cell percentages in 
bone marrow using flow cytometry (B220/CD138 and PNA/B220). To stimulate 
formation of germinal centers and plasma cell maturation, these mice will be 
challenged with antigen (sheep red blood cells [19] or nitrophenyl-conjugated 
chicken gammaglobulin (NP-CGG;) [20] and the plasma cell compartment will be 
assessed as just described.  
 
Preliminary data suggests Rb1+/-p107-/- are born at reduced frequencies than 
expected from Mendelian ratios (Table 1). Specifically, when Rb1+/+p107-/- were 
mated to Rb1+/-p107+/- mice, zero Rb1+/-p107-/- mice were born. The expected 
frequency is 25% (of 27 pups total, expected 6 Rb1+/-p107-/- mice). When Rb1+/-
p107+/- mice were mated to Rb1+/-p107+/-, the expected frequency of Rb1+/-p107-/- 
pups is 12.5%, but only 2 mice (of 83 pups total, 2.4%) were born.  Also, Rb1+/- 
mice succumb to pituitary tumors at 8 months [21]. We are therefore generating 
mice with conditional deletion of Rb1 in plasma cells by mating Rb1flox/flox [22] 
mice (provided by Tyler Jacks) to mice that express Cre recombinase only when 
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transcription of Cγ1 (IgG1) heavy chain occurs in germinal centers upon 
stimulation with T cell dependent antigens [23] (provided by Klaus Rajewsky). 
These mice will have Rb1 deletions in most germinal center B cells. We will mate 
these mice to p107-/- mice to generate Cγ1CreRb1+/+p107-/- and 
Cγ1CreRb1Flox/+p107-/- mice. These mice will be assessed as above, for 
alterations in the plasma cell compartments. If haploinsufficiency of Rb1  
contributes to myelomagenesis, then we predict plasma cell development will be 
affected in the Cγ1CreRb1Flox/+p107-/- mice but not in the Cγ1CreRb1+/+p107-/- 
mice.   
 
If true, we may anticipate that patients with hereditary retinoblastoma that harbor 
germline loss of one copy of RB1 allele have an increased propensity for 
development of MGUS. Currently, there are no reports of increased incidence of 
MM in retinoblastoma patients. Since MGUS is asymptomatic, however, it 
remains a formal possibility that retinoblastoma patients have increased 
propensity for development of MGUS that has yet to be described.  To address 
this hypothesis, serum samples of surviving retinoblastoma patients will be 
subject to serum SPEP and immunofixation analysis to examine for elevated and 
monoclonal serum antibodies, respectively. If true, this supports the hypothesis 
RB1 haploinsufficiency contributes to alteration of PC’s in humans. If not, it 
suggests in humans, development of MGUS may require additional mutations.  
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5.3 Hypothesis 2: NBEA is targeted by mutations in MM 
Array CGH analysis revealed NBEA was a deletion target in MGUS and MM 
patient samples (Chapter 2). Our large-scale microarray expression analysis 
using published databases to examine NBEA transcripts in 262 patient samples 
revealed NBEA levels were decreased in primary patient samples harboring 
monosomy chromosome 13 versus patient samples that retained both alleles, 
(Chapter 4) suggesting NBEA could function as a tumor suppressor. However, 
further analysis using Q-RT-PCR and Western blotting, revealed a subset of 
primary patient samples harbored high levels of NBEA. Mutations in the p53 
tumor suppressor gene lead to elevated P53 levels, and expression of 
functionally inactive protein [24]. To determine if the NBEA gene is a target of 
mutations in myeloma, complete sequencing of NBEA on DNA isolated from 
purified CD138 patient plasma cells will be performed at the Washington 
University Genome Sequencing Center.   
 
5.4 Hypothesis 3: Expression of NBEA contributes to myelomagenesis 
A subset of MM patient samples harbored robust expression of NBEA and  
SiRNA-mediated knockdown of NBEA in OPM2 cells led to growth reduction 
(Chapter 4), suggesting expressed NBEA provides a survival signal. We have 
undertaken the task of subcloning the entire NBEA cDNA for use in 
overexpression studies. We initially planned on using a retroviral-mediated high- 
level expression and bone marrow transplantation system to express NBEA in 
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murine hematopoietic cells, but the large size of NBEA is too big for efficient 
packaging into retrovirus.  
 
A DNA construct is currently being generated that is predicted to direct 
expression of NBEA to B cells using the Eµ regulatory sequences in a transgenic 
mouse model.  To determine whether expression of NBEA alters plasma cell 
development, serum will be analyzed every three months for detection of 
monoclonal protein by performing serum electrophoresis and immunofixation 
analysis. Total levels of serum protein will be assessed using serum protein 
electrophoresis (SPEP) analysis. We will assess for detection of increased 
plasma cell numbers in bone marrow using flow cytometry (B220/CD138 and 
PNA/B220). To stimulate formation of germinal centers and assess for altered 
plasma cell function, these mice will be challenged with antigen (sheep red blood 
cells [19] or or nitrophenyl-conjugated chicken gammaglobulin (NP-CGG;) [20] 
and the plasma cell compartment will be assessed as just described. 
 
The original NBEA cDNA that we amplified from a primary patient sample 
revealed an unexpected insertion of intron 1 (296 base pairs). We are currently 
PCR amplifying NBEA 5’ regions from first strand cDNA generated from RNA 
isolated from a normal human brain sample (kindly provided by William Schmidt, 
WUSM). PCR products will be subcloned and DNA sequenced to determine if 
transcription of intron 1 is tumor-associated. 
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Our aCGH analysis revealed two of the patient samples in our study harbored 
interstitial deletions affecting part of the NBEA locus (Chapter 2). In sample 
95295, copy number decrease affected exons 3-19 and in sample 64511, exons 
1-9 were affected. First strand cDNA will be generated from RNA templates from 
each of these patient samples and amplified products will be analyzed by 
sequence analysis. If shortened transcripts are detected, they will be subcloned 
into an expression vector and expression of altered protein will be determined. 
Altered NBEA could behave as a ‘dominant negative’ leading to an effective 
NBEA null state, or alternatively, confer a gain of function. If truncated proteins 
are detected, we will generate mice expressing these tumor-associated forms of 
NBEA in B cells under the Eµ regulatory sequences. They will be analyzed for 
MGUS or myeloma development as described above.  If however, truncated 
NBEA is not expressed in these samples, it remains a future interest to 
determine why elevated levels of NBEA transcripts are detected in these patient 
samples from the other NBEA allele.  
 
5.5 Hypothesis 4: High expression of NBEA cooperates with Rb1 
haploinsufficiency in myeloma development  
A central finding of our aCGH analysis was that all patient samples with 
interstitial deletions affecting RB1 also harbored interstitial deletions affecting 
NBEA, and that a subset of patient samples even with monosomy 13, harbored 
elevated NBEA expression (Chapter 2), suggesting alteration of these two genes 
 154 
cooperate in myelomagenesis. To determine if NBEA expression cooperates with 
Rb1 haploinsufficiency in plasma cells, we will mate our Cγ1CreRb1Flox/Floxp107-/- 
mice to EµNBEA mice that express NBEA in the B cell compartment to generate 
EµNBEACγ1CreRb1Flox/+p107-/- and EµNBEACγ1CreRb1+/+p107-/- mice. These 
mice will be assessed for abnormalities in plasma cells as described above. 
 
5.6 Determine spleen cell subtype that expresses Nbea  
We showed Nbea was dispensable for engraftment and development of adult 
steady state hematopoeisis using a fetal liver transplant system (Chapter 4). 
This was somewhat surprising since we found Nbea was expressed in spleen 
and thymus (Chapter 4). A report modeling lymphoid tumors with 
plasmablast/post germinal phenotypes revealed Nbea was upregulated over six 
fold when compared to a related model with a more immature/pre germinal 
center phenotype, suggesting Nbea could be developmentally regulated [25]. 
Combined with its relatively low level in spleen, its dysregulation in plasma cell 
dyscrasias, and expression in another secretory cell type (neurons), we posit 
Nbea could be expressed in normal plasma cells. To determine if Nbea is 
expressed in antigen stimulated plasma cells, mice will be challenged with sheep 
red blood cells and plasma cells will be sorted using cell surface markers 
PNA/B220 one week post injection when formation of spleen GCs are maximal 
[19]. Q-RT-PCR will be used to quantitively assess Nbea expression in these 
cells.  
 
 155 
To determine the spleen localization of Nbea we will perform IHC staining for 
Nbea in murine spleen sections. We are currently testing a rabbit polyclonal 
Nbea antibody we have had made (Dan Crimmins, Cortex) for this purpose. 
Additionally, experiments are underway to sort spleen cell subsets based on cell 
surface expression of cell type specific markers (GR-1, B220, CD4, CD8, DX5) 
followed by Q-RT-PCR to determine in what spleen cell type Nbea transcripts are 
expressed in basal conditions.  
 
5.7 Hypothesis 5: Nbea is required for plasma cell functions  
 
If NBEA functions in vesicle traffic or PKA mediated regulation of AID in class 
switch recombination (CSR) or secretion, Nbea null plasma cells may have 
deficiencies in antibody formation and/or secretion. To assess this, we will use 
our fetal liver transplantation system to generate mice with null or wild type Nbea 
hematopoietic systems (Chapter 4). In vivo analysis of basal CSR will be 
assessed by performing ELISA assays on serum and levels of IgM, IgG1, IgG2a, 
IgG2B, IgG3 and IgA will be determined [26]. If Nbea null chimeras are deficient 
in CSR, it predicts detection of IgM (which does not undergo CSR), but not the 
other isotypes. If there are secretion defects, detection of all antibody isotypes is 
predicted to be low/undetectable.  
 
To assess CSR in an antigen stimulated system, mice will be injected with SRBC 
and serum will be subject to ELISA for IgM and IgG1. In vitro assessment of 
class switch recombination will be performed by isolating splenocytes (CD43 
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depletion) from engrafted mice (Nbea+/+ and Nbea-/-) by stimulating purified B cell 
splenocytes with LPS, LPS and Il-4, pr LPS and TGFβ and then quantitating 
antibody isotypes in culture supernatents by ELISA as described above [26-28].  
 
5.8 Hypothesis for cellular function of NBEA in PC Diseases 
Our data implicate a role for NBEA in plasma cell dyscrasias, but its role in 
normal plasma cell and/pr malignant plasma cell development remains unclear.  
Below are three hypotheses for cellular functions NBEA could play a role in 
altering that may (or may not) contribute to diseased plasma cells.  
 
5.8A NBEA may facilitate PKA-mediated alteration of class switch 
recombination (CSR) 
NBEA domains provide clues to potential mechanistic roles for NBEA in plasma 
cell dyscrasias. NBEA transcript encodes a PKA binding domain, and murine 
Nbea binds to two PKA regulatory subunits (RIIα (Kd: 10nM) and RIIβ  (Kd: 
30nM); [28]. Since the core region responsible for PKA binding is absolutely 
conserved between mouse and human, human NBEA likely also binds these 
subunits. Recent data has illustrated phosphorylation of Serine 38 of the 
activation induced cytidine deaminase (AID) protein is mediated by the catalytic 
subunit of PKA (PKAcα) [27]. AID is the enzyme responsible for generating 
double stranded breaks required for class switch recombination (CSR) and 
somatic hypermutation (SHM) processes in antibody maturation.  PKA enzymes 
are regulated by localization via binding to anchoring proteins (AKAPs) that 
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ensure PKA only phosphorylates appropriate targets at specific cellular locations. 
The AKAP that targets PKA to sites of CSR has not been identified. 
 
In the context of PC dyscrasias, expressed NBEA may inappropriately target 
PKA to sites of CSR, leading to increased AID phosphorylation and activation, 
resulting in extra formation of double strand breaks that would otherwise not 
occur. This is consistent with the model that it is during recombination events in 
antibody production where aneuploidy in MM occurs. NBEA could affect PKA 
localization via a number of mechanisms, depending on whether it is wild type or 
mutated in myeloma. NBEA in rat neurons is localized near the nucleus and 
within the golgi network [28], however in MGUS and MM cells, NBEA may be 
mislocalized to the nucleus, resulting in extra pools of PKA localized to sites of 
AID activation. Alternatively, if NBEA normally binds PKA in the cytoplasm/golgi, 
where pools of PKA are found, mutations in NBEA may result in decreased 
binding, resulting in increased amounts of PKA localizing to sites of CSR. 
Localization studies are required to determine where NBEA and PKA are 
localized in normal, MGUS and MM plasma cells. 
 
AID is required for mature plasma cell cancers in a model of Myc/BCL6 over-
expression in mice [25], and Nbea expression was increased in tumor cells 
isolated from this model with plasma cell characteristics compared to tumors of 
an earlier B stage [25].  Generating mice with plasma cell specific deletions of 
Nbea (Cγ1Cre NbeaFlox/Flox) could be used to determine if it is required in this 
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model. If Nbea promotes formation of monoclonal antibody or aneuploidy due to 
double stranded breaks via regulation of PKA mediated CSR, it predicts 
monoclonal antibody production and disease phenotypes in this mouse model 
would revert to a functionally less mature stage, just like they do when the 
MYC/BCL6 mice are mated to Aid (Aicda) null mice [25].  
 
5.8B NBEA alters vesicle formation, function, or trafficking 
Because other proteins with BEACH/WD40 domains are implicated in vesicle 
formation or trafficking [28-30], and because subcellular localization studies of 
Nbea that revealed it localizes in perinuclear clusters near the trans side of golgi 
complexes and small tubulovesicular structures [28], perhaps NBEA (mutated or 
normal) in MM alters normal vesicle function, formation, or trafficking. Plasma 
cells (normal and diseased) generate, produce, and secrete large amounts of 
antibody via the secretory pathway. Nbea may enhance vesicle formation leading 
to enhanced secretion of immunoglobulin molecules. Alternatively, altered Nbea 
may result in inappropriate vesicle trafficking such that signaling molecules are 
misdirected in the cell i.e. such that proper lysosomal degradation of vesicles 
and/or cargo does not occur, resulting in increased signaling. Electron 
microscopy of vesicle structure and Nbea localization in MGUS and MM plasma 
cells can be used to address the hypothesis that Nbea alters vesicle traffic.  
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5.8C NBEA may provide a survival signal mediated by NFκB  
NBEA may provide a survival signal in a general context by altering the 
NFκB pathway via its PKA domain. This is consistent with chromosome 13 
deletions being detected early in MM stages including MGUS, and that during 
much of MM, plasma cells cycle slow, but avoid apoptosis. As stated above, 
human NBEA likely binds to PKA regulatory subunits. The catalytic subunits of 
PKA can phosphorylate the p65 member of the canonical NFκB family [32]. 
NFκB activating mutations affecting the non-canonical pathway are detected in 
MM samples [33], leading to constitutive activation. Perhaps NBEA activates, via 
PKA, the canonical NFκB pathway, in a mutually exclusive fashion to cells with 
non-canonical NFκB mutations.  Although there is evidence for two separate 
“pools” of PKA catalytic subunits, [31] (one pool bound to IκB subunits and the 
other to PKA regulatory subunits), binding of PKA to NBEA (or not, if it is 
mutated) may alters this pool, such that more PKA catalytic subunits are free to 
phosphorylate downstream targets.  Dysregulation of NBEA may be necessary 
but not sufficient to transform a normal PC to MGUS or MM via its ability to 
confer survival signals.  
 
Although much needs to be done, we have provided a useful framework for 
pursuing the role of RB1 and NBEA may play in normal and altered plasma cell 
development and have developed important reagents that will facilitate future 
experiments. 
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